Research Radartracking 903 published studies · 231 human · 5 safety signals · 33 clinical trials · 44 cancer pages · updated Jul 2026Open the Research Map →

Breast Invasive Ductal Carcinoma (IDC)

The most common invasive breast cancer. Biology-driven care hinges on ER/PR, HER2, Ki-67, nodal status, stage, and genomic assays.

Educational only: This page is not medical advice. Coordinate decisions with your oncology team.

Reviewed Jun 2026 · site editor · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed· last updated Jun 2026

Evidence at a glanceHuman trial / meta-analysisMixed results⚠ Studies disagree
35 published studies that name Breast Invasive Ductal Carcinoma (IDC)7 human studies approved & graded (trial, observational, or meta-analysis)164 human clinical studies in the Breast Invasive Ductal Carcinoma (IDC) corpus2374 source documents in the Breast Invasive Ductal Carcinoma (IDC) corpus

last checked June 20, 2026

Why this grade?

Human trial / meta-analysisIncludes human trial or meta-analysis evidence.

Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.

What the guidelines say

NCI PDQESMONCCNASCO

We link the authoritative guidelines rather than reproduce them. Below, the treatments on this page are split into standard care, guideline or regulatory options, supportive care, and studied but not standard so established care is not mixed with experimental or supportive items.

Standard care - guideline-backed
  • Breast-conserving surgery (lumpectomy) + SLNB when feasible
  • Mastectomy when disease extent, multicentricity, prior RT, or patient preference dictates; nipple-sparing
  • Immediate reconstruction planning (implant or autologous)
  • Z0011 approach: omit ALND with 1–2 positive SLNs if lumpectomy + whole-breast RT
  • Targeted axillary dissection post-NAT for initially node-positive patients (retrieve clipped node + SLNs) to accurately restage and potentially de-escalate ALND
  • Re-excision for positive margins; for invasive cancer, ‘no ink on tumor’
  • Place surgical clips in the tumor bed to guide boost RT and future imaging
  • Whole-breast irradiation (WBI) after lumpectomy
  • Tumor-bed boost for higher local-recurrence risk (younger age, close margins, high grade, extensive intraductal component)
  • Post-mastectomy radiation (PMRT) for ≥4 positive nodes
  • Regional nodal irradiation (RNI) to axillary/supraclavicular ± internal mammary nodes based on nodal burden, biology, and response to NAT
  • Deep-inspiration breath hold (DIBH) for left-sided WBI/PMRT to reduce heart dose
  • Stereotactic radiosurgery (SRS) for limited brain metastases
  • Partial-breast irradiation (PBI)
  • HR+/HER2– early: endocrine therapy (tamoxifen or aromatase inhibitor) ± ovarian function suppression (OFS) based on menopausal status and risk
  • Use genomic assays to decide on adjuvant chemotherapy in HR+/HER2– node-negative and select 1–3 node-positive patients undergoing upfront surgery
  • High-risk, node-positive HR+/HER2–: consider adjuvant abemaciclib + endocrine therapy per eligibility criteria
  • Postmenopausal HR+/HER2–: consider adjuvant bisphosphonates to reduce bone recurrence and fractures
  • Metastatic HR+/HER2–: endocrine therapy + CDK4/6 inhibitor
  • HER2+ stage II–III: neoadjuvant taxane-based ± anthracycline + trastuzumab/pertuzumab
  • Small node-negative HER2+ (e
  • Metastatic HER2+: first line taxane + trastuzumab + pertuzumab; second line trastuzumab deruxtecan (T-DXd) preferred; later lines
  • High-risk early TNBC: neoadjuvant anthracycline/taxane ± platinum with pembrolizumab
  • gBRCA-mutated, high-risk HER2– (HR+ or TNBC): consider 1 year of adjuvant olaparib per criteria
  • Metastatic TNBC: PD-L1–positive → pembrolizumab + chemotherapy; later lines
  • Ovarian protection: consider GnRH agonist during chemotherapy for premenopausal patients to reduce ovarian failure risk and preserve fertility
  • Oligometastatic disease: discuss consolidative local therapy (SBRT, surgery) after systemic response in a multidisciplinary tumor board
  • AC-T (doxorubicin/cyclophosphamide → paclitaxel) (early/high-risk)
  • TC (docetaxel/cyclophosphamide) (early)
  • THP / TCHP (taxane ± carboplatin + trastuzumab/pertuzumab) (HER2+ neoadjuvant)
  • Capecitabine (post-neoadjuvant TNBC residual)
  • CDK4/6 + endocrine therapy (AI or fulvestrant)
  • Post-CDK4/6 progression: re-profile (tumor or ctDNA)
  • Alpelisib for PIK3CA-mutant HR+/HER2– after AI
  • Capivasertib + fulvestrant improves outcomes in tumors with PI3K/AKT/PTEN alterations
  • Everolimus + exemestane restores endocrine sensitivity in some AI-resistant HR+
  • Adjuvant abemaciclib for high-risk node-positive HR+/HER2– improves IDFS when added to endocrine therapy (strict eligibility)
  • PARP inhibitors (olaparib/talazoparib) for gBRCA/PALB2: adjuvant (select high-risk HER2–) and metastatic
  • Later-line ADCs in HR+/HER2–: sacituzumab govitecan after endocrine + targeted therapies
  • HER2 sequence (metastatic): taxane + trastuzumab/pertuzumab → trastuzumab deruxtecan (T-DXd) → tucatinib + trastuzumab + capecitabine (brain-active) → other TKIs (neratinib/lapatinib) case-by-case
  • Residual disease after neoadjuvant HER2 therapy: switch to adjuvant T-DM1 to reduce recurrence risk
  • Extended adjuvant neratinib for high-risk HR+/HER2+ after trastuzumab (diarrhea prophylaxis mandatory) — center-specific use
  • T-DXd active in HER2-low (IHC 1+ or 2+/ISH–) metastatic after prior lines — emphasize ILD vigilance and early drug holds if symptomatic
  • Pembrolizumab for high-risk early TNBC (neoadjuvant + adjuvant) improves pCR/EFS
  • Sacituzumab govitecan
  • gBRCA TNBC benefits from PARP inhibitors (metastatic) and adjuvant olaparib (select early)
  • Platinum agents
  • HER2+ CNS disease: tucatinib-based regimens
  • Oligometastatic scenarios (all subtypes): consider SBRT or surgery after systemic response in tumor board
  • Rare MSI-H/TMB-H/NTRK fusion
Guideline / FDA options - context-specific
  • anastrozole
  • tamoxifen
Supportive care - symptom / survivorship support
  • Lymphedema program: prehab education, early PT/OT, compression fitting, and progressive weight training
  • Shoulder mobility & scar management: early ROM, myofascial techniques, and desensitization to prevent frozen shoulder and chronic pain
  • Menopause symptom toolkit on endocrine therapy: non-hormonal options (SSRIs/SNRIs, gabapentin, clonidine), vaginal moisturizers/lubricants, and pelvic floor therapy
  • Sexual health: address dyspareunia, libido, and body image
  • AI bone program: weight-bearing/resistance exercise, vitamin D/calcium, baseline and periodic DEXA
  • Cardio-oncology: manage BP, lipids, diabetes
  • Return-to-work & cognitive rehab: graded return plan, fatigue pacing, occupational therapy, and ‘chemo-brain’ strategies (sleep hygiene, cognitive exercises)
  • Alopecia and neuropathy mitigation: scalp cooling during sensitive chemo
  • Stomatitis prevention: steroid mouthwash with everolimus
  • GI playbooks: diarrhea (abemaciclib/capecitabine/sacituzumab) start loperamide early
  • Pulmonary vigilance: new cough/dyspnea/fever on T-DXd or everolimus → urgent ILD/pneumonitis evaluation and drug hold
  • Dermatologic care: alpelisib/capivasertib rash prophylaxis (non-sedating antihistamines), urea-based emollients
  • Metabolic monitoring: proactive glucose/A1c and dietitian input with alpelisib/capivasertib
  • Multimodal analgesia: NSAIDs/acetaminophen, neuropathic agents (duloxetine for CIPN), interventional options when needed
  • Sleep, anxiety, and mood: CBT-I, mindfulness, exercise
  • Vaccination plan: inactivated vaccines per guidelines
  • Port care: educate on infection/DVT signs
  • Navigation and financial counseling: transportation, work leave, medication access, and clinical trial matching to reduce care gaps
Studied, not standard - investigational
  • endocrine therapy
  • estrogen therapy / hormone therapy (ET/HT)
  • Primary endocrine therapy
  • Adjuvant systemic therapy
  • Bone-modifying drugs
  • Neoadjuvant systemic treatment options
  • Supportive care
  • axillary lymph node dissection (ALND)
  • breast-conserving surgery (BCS)
  • breast MRI (diagnostic)
  • breast MRI (screening)
  • breast ultrasound (diagnostic)
  • Breath-hold techniques (e.g., deep-inspiration breath hold)
  • diagnostic mammography and tomosynthesis
  • immediate breast reconstruction (lumpectomy reconstruction)
  • mammography and digital breast tomosynthesis
  • mammography (male screening)
  • mastectomy
  • Oncoplastic Breast Surgery
  • re-excision
  • sentinel lymph node biopsy (SLNB)
  • surgical resection
  • Accelerated partial breast irradiation (APBI)
  • Hypofractionated whole-breast irradiation
  • intraoperative radiation therapy
  • Intraoperative radiotherapy
  • postmastectomy radiation therapy (PMRT)
  • Postmastectomy radiotherapy (PMRT) to chest wall and supraclavicular nodes
  • radiation therapy (RT)
  • Radiotherapy
  • regional nodal irradiation (RNI)
  • Regional nodal irradiation (supraclavicular)
  • Single-fraction radiotherapy (8 Gy) for bone metastases
  • stereotactic ablative body radiotherapy (SBRT)
  • Boost dose over the tumour bed
  • whole-breast radiation therapy (whole-breast RT)
  • capivasertib
  • CDK4/6 inhibitors
  • PIK3CA inhibitors
  • Targeted therapies
  • Surgery
  • Whole-brain radiotherapy
  • Stereotactic radiosurgery
  • Memantine
  • Hippocampal avoidance
  • Axillary irradiation
  • bone-modifying agents
  • targeted systemic therapy
  • ?
  • anti-HER2 therapy
  • bilateral risk-reducing mastectomy (BRRM)
  • Aromatase inhibitors
  • Ovarian suppression
  • Immunotherapeutic agent
  • Risk-reducing bilateral salpingo-oophorectomy
  • exemestane
  • raloxifene
  • Gonadotrophin-releasing hormone agonists (GnRHa)
  • sperm, oocyte, and embryo cryopreservation
  • bisphosphonates
  • zoledronic acid
  • denosumab
  • acupuncture
  • acupressure
  • aloe vera
  • ginger
  • ginseng
  • Acetyl-L-carnitine
  • Fuzuloparib

Read the guidelines

Cancer-specific deep links aren’t curated yet — these search the authoritative sources for Breast Invasive Ductal Carcinoma (IDC).

Treatment map: Breast Invasive Ductal Carcinoma (IDC)

Open as a full page →

Standard care plus every compound studied in the literature (each cited) and graded by evidence, organized by clinical readiness. A category, not a verdict that anything works — confirm anything here with your oncology team.

127
Interventions
50
Standard of care
29
Tested in people
1
Lab / animal
45
Named in lit.
9
Classes
Standard of care (50) Guideline option (2) Tested in people (29) Lab / animal only (1) Named in the literature (45)

Tested in people, by trial phase: phase not reported ×29

Clinical evidence
Preclinical evidence
Standard of care
Guideline option
Tested in people
Lab / animal only
Named in the literature
Surgery & procedures
7
11
11
Radiotherapy
9
6
14
Chemotherapy
6
Targeted therapy
15
1
6
Immunotherapy
4
1
Hormonal therapy
9
2
5
6
Repurposed drugs
1
2
Supplements & natural agents
4
Other
1
1
5

Columns group into clinical evidence (used in, or tested on, people) and preclinical evidence (lab/animal, or only named in the literature). Cell = number of interventions; a dashed cell means none recorded there.

Established care — detail (52)
Surgery & procedures
Breast-conserving surgery (lumpectomy) + SLNB when feasible
Breast-conserving surgery (lumpectomy) + SLNB when feasible; oncoplastic techniques expand eligibility and cosmesis.
CurativeStandardCurated
Mastectomy when disease extent, multicentricity, prior RT, or patient preference dictates; nipple-sparing
Mastectomy when disease extent, multicentricity, prior RT, or patient preference dictates; nipple-sparing is feasible in selected cases with careful margin assessment.
CurativeStandardCurated
Immediate reconstruction planning (implant or autologous)
Immediate reconstruction planning (implant or autologous) should be coordinated with anticipated radiation to minimize complications and optimize outcomes.
CurativeStandardCurated
Z0011 approach: omit ALND with 1–2 positive SLNs if lumpectomy + whole-breast RT
Z0011 approach: omit ALND with 1–2 positive SLNs if lumpectomy + whole-breast RT is planned and no gross extranodal extension.
CurativeStandardCurated
Targeted axillary dissection post-NAT for initially node-positive patients (retrieve clipped node + SLNs) to accurately restage and potentially de-escalate ALND
Targeted axillary dissection post-NAT for initially node-positive patients (retrieve clipped node + SLNs) to accurately restage and potentially de-escalate ALND.
CurativeStandardCurated
Re-excision for positive margins; for invasive cancer, ‘no ink on tumor’
Re-excision for positive margins; for invasive cancer, ‘no ink on tumor’ is adequate. For pure DCIS, aim ≥2 mm.
CurativeStandardCurated
Place surgical clips in the tumor bed to guide boost RT and future imaging
Place surgical clips in the tumor bed to guide boost RT and future imaging.
CurativeStandardCurated
Radiotherapy
Whole-breast irradiation (WBI) after lumpectomy
Whole-breast irradiation (WBI) after lumpectomy is standard; hypofractionation preferred for most (e.g., ~3 weeks). Five-fraction regimens are reasonable in selected patients.
StandardCurated
Tumor-bed boost for higher local-recurrence risk (younger age, close margins, high grade, extensive intraductal component)
Tumor-bed boost for higher local-recurrence risk (younger age, close margins, high grade, extensive intraductal component).
StandardCurated
Post-mastectomy radiation (PMRT) for ≥4 positive nodes
Post-mastectomy radiation (PMRT) for ≥4 positive nodes; consider for 1–3 positive nodes with additional risk factors (large tumor, LVI, close margins).
StandardCurated
Regional nodal irradiation (RNI) to axillary/supraclavicular ± internal mammary nodes based on nodal burden, biology, and response to NAT
Regional nodal irradiation (RNI) to axillary/supraclavicular ± internal mammary nodes based on nodal burden, biology, and response to NAT.
StandardCurated
Deep-inspiration breath hold (DIBH) for left-sided WBI/PMRT to reduce heart dose
Deep-inspiration breath hold (DIBH) for left-sided WBI/PMRT to reduce heart dose; consider proton therapy in select complex IMN cases.
StandardCurated
Stereotactic radiosurgery (SRS) for limited brain metastases
Stereotactic radiosurgery (SRS) for limited brain metastases; SBRT for oligometastatic bone/liver/lung lesions case-by-case.
Advanced / metastaticStandardCurated
Partial-breast irradiation (PBI)
Partial-breast irradiation (PBI) can be considered for carefully selected low-risk early cases as a shorter alternative to WBI.
StandardCurated
Oligometastatic disease: discuss consolidative local therapy (SBRT, surgery) after systemic response in a multidisciplinary tumor board
Oligometastatic disease: discuss consolidative local therapy (SBRT, surgery) after systemic response in a multidisciplinary tumor board.
Advanced / metastaticStandardCurated
Oligometastatic scenarios (all subtypes): consider SBRT or surgery after systemic response in tumor board
Oligometastatic scenarios (all subtypes): consider SBRT or surgery after systemic response in tumor board.
Advanced / metastaticStandardCurated
Chemotherapy
Ovarian protection: consider GnRH agonist during chemotherapy for premenopausal patients to reduce ovarian failure risk and preserve fertility
Ovarian protection: consider GnRH agonist during chemotherapy for premenopausal patients to reduce ovarian failure risk and preserve fertility.
StandardCurated
AC-T (doxorubicin/cyclophosphamide → paclitaxel) (early/high-risk)
Common adjuvant/neoadjuvant backbone; monitor cardiotoxicity and neuropathy.
StandardCurated
TC (docetaxel/cyclophosphamide) (early)
Non-anthracycline option; consider in lower cardiac reserve.
StandardCurated
THP / TCHP (taxane ± carboplatin + trastuzumab/pertuzumab) (HER2+ neoadjuvant)
Preferred for stage II–III HER2+; adapt adjuvant based on pCR/residual disease.
NeoadjuvantStandardCurated
Capecitabine (post-neoadjuvant TNBC residual)
Improves outcomes in residual TNBC after neoadjuvant chemo.
NeoadjuvantStandardCurated
Platinum agents
Platinum agents remain valuable in TNBC (particularly HRD contexts).
StandardCurated
Targeted therapy
Use genomic assays to decide on adjuvant chemotherapy in HR+/HER2– node-negative and select 1–3 node-positive patients undergoing upfront surgery
Use genomic assays to decide on adjuvant chemotherapy in HR+/HER2– node-negative and select 1–3 node-positive patients undergoing upfront surgery.
AdjuvantStandardCurated
Postmenopausal HR+/HER2–: consider adjuvant bisphosphonates to reduce bone recurrence and fractures
Postmenopausal HR+/HER2–: consider adjuvant bisphosphonates to reduce bone recurrence and fractures.
AdjuvantStandardCurated
HER2+ stage II–III: neoadjuvant taxane-based ± anthracycline + trastuzumab/pertuzumab
HER2+ stage II–III: neoadjuvant taxane-based ± anthracycline + trastuzumab/pertuzumab; if residual disease, switch to adjuvant T-DM1 to complete ~1 year of anti-HER2 therapy.
NeoadjuvantStandardCurated
Small node-negative HER2+ (e
Small node-negative HER2+ (e.g., T1a/b): consider paclitaxel + trastuzumab (TH) adjuvant de-escalation for appropriate candidates.
AdjuvantStandardCurated
Metastatic HER2+: first line taxane + trastuzumab + pertuzumab; second line trastuzumab deruxtecan (T-DXd) preferred; later lines
Metastatic HER2+: first line taxane + trastuzumab + pertuzumab; second line trastuzumab deruxtecan (T-DXd) preferred; later lines include tucatinib + trastuzumab + capecitabine (especially with brain mets), neratinib- or lapatinib-based regimens as appropriate.
Advanced / metastaticStandardCurated
gBRCA-mutated, high-risk HER2– (HR+ or TNBC): consider 1 year of adjuvant olaparib per criteria
gBRCA-mutated, high-risk HER2– (HR+ or TNBC): consider 1 year of adjuvant olaparib per criteria.
AdjuvantStandardCurated
Alpelisib for PIK3CA-mutant HR+/HER2– after AI
Alpelisib for PIK3CA-mutant HR+/HER2– after AI; start glucose monitoring and rash prophylaxis (non-sedating antihistamine).
StandardCurated
PARP inhibitors (olaparib/talazoparib) for gBRCA/PALB2: adjuvant (select high-risk HER2–) and metastatic
PARP inhibitors (olaparib/talazoparib) for gBRCA/PALB2: adjuvant (select high-risk HER2–) and metastatic; plan for anemia monitoring and contraception.
AdjuvantStandardCurated
HER2 sequence (metastatic): taxane + trastuzumab/pertuzumab → trastuzumab deruxtecan (T-DXd) → tucatinib + trastuzumab + capecitabine (brain-active) → other TKIs (neratinib/lapatinib) case-by-case
HER2 sequence (metastatic): taxane + trastuzumab/pertuzumab → trastuzumab deruxtecan (T-DXd) → tucatinib + trastuzumab + capecitabine (brain-active) → other TKIs (neratinib/lapatinib) case-by-case.
Advanced / metastaticStandardCurated
Residual disease after neoadjuvant HER2 therapy: switch to adjuvant T-DM1 to reduce recurrence risk
Residual disease after neoadjuvant HER2 therapy: switch to adjuvant T-DM1 to reduce recurrence risk.
NeoadjuvantStandardCurated
Extended adjuvant neratinib for high-risk HR+/HER2+ after trastuzumab (diarrhea prophylaxis mandatory) — center-specific use
Extended adjuvant neratinib for high-risk HR+/HER2+ after trastuzumab (diarrhea prophylaxis mandatory) — center-specific use.
AdjuvantStandardCurated
T-DXd active in HER2-low (IHC 1+ or 2+/ISH–) metastatic after prior lines — emphasize ILD vigilance and early drug holds if symptomatic
T-DXd active in HER2-low (IHC 1+ or 2+/ISH–) metastatic after prior lines — emphasize ILD vigilance and early drug holds if symptomatic.
Advanced / metastaticStandardCurated
Sacituzumab govitecan
Sacituzumab govitecan is a preferred later-line option in metastatic TNBC; early use of growth-factor support and loperamide reduces dose-limiting toxicity.
Advanced / metastaticStandardCurated
gBRCA TNBC benefits from PARP inhibitors (metastatic) and adjuvant olaparib (select early)
gBRCA TNBC benefits from PARP inhibitors (metastatic) and adjuvant olaparib (select early).
AdjuvantStandardCurated
HER2+ CNS disease: tucatinib-based regimens
HER2+ CNS disease: tucatinib-based regimens provide intracranial responses; integrate SRS/surgery with neuro-oncology.
StandardCurated
Immunotherapy
High-risk early TNBC: neoadjuvant anthracycline/taxane ± platinum with pembrolizumab
High-risk early TNBC: neoadjuvant anthracycline/taxane ± platinum with pembrolizumab; continue adjuvant pembrolizumab. If residual disease, add adjuvant capecitabine.
NeoadjuvantStandardCurated
Metastatic TNBC: PD-L1–positive → pembrolizumab + chemotherapy; later lines
Metastatic TNBC: PD-L1–positive → pembrolizumab + chemotherapy; later lines include sacituzumab govitecan; gBRCA mutation → PARP inhibitor considered.
Advanced / metastaticStandardCurated
Pembrolizumab for high-risk early TNBC (neoadjuvant + adjuvant) improves pCR/EFS
Pembrolizumab for high-risk early TNBC (neoadjuvant + adjuvant) improves pCR/EFS; in metastatic TNBC, add to chemo for PD-L1–positive disease.
NeoadjuvantStandardCurated
Rare MSI-H/TMB-H/NTRK fusion
Rare MSI-H/TMB-H/NTRK fusion can unlock tumor-agnostic immunotherapy/TRK inhibitors; screen with broad NGS when feasible.
StandardCurated
Hormonal therapy
HR+/HER2– early: endocrine therapy (tamoxifen or aromatase inhibitor) ± ovarian function suppression (OFS) based on menopausal status and risk
HR+/HER2– early: endocrine therapy (tamoxifen or aromatase inhibitor) ± ovarian function suppression (OFS) based on menopausal status and risk; duration typically 5 years, extend to 7–10 years for selected higher-risk cases.
StandardCurated
High-risk, node-positive HR+/HER2–: consider adjuvant abemaciclib + endocrine therapy per eligibility criteria
High-risk, node-positive HR+/HER2–: consider adjuvant abemaciclib + endocrine therapy per eligibility criteria.
AdjuvantStandardCurated
Metastatic HR+/HER2–: endocrine therapy + CDK4/6 inhibitor
Metastatic HR+/HER2–: endocrine therapy + CDK4/6 inhibitor is standard first line. On progression, personalize by biomarkers (ESR1 → SERD; PIK3CA → alpelisib + fulvestrant; AKT1/PTEN/PIK3CA → capivasertib + fulvestrant; consider everolimus combinations). Later-line ADCs (e.g., sacituzumab govitecan) are options.
Advanced / metastaticStandardCurated
CDK4/6 + endocrine therapy (AI or fulvestrant)
CDK4/6 + endocrine therapy (AI or fulvestrant) is first-line standard for metastatic HR+/HER2–; choose agent by comorbidity (e.g., ribociclib OS data; abemaciclib diarrhea but less neutropenia).
Advanced / metastaticStandardCurated
Post-CDK4/6 progression: re-profile (tumor or ctDNA)
Post-CDK4/6 progression: re-profile (tumor or ctDNA). ESR1 mutation → SERD strategy (e.g., fulvestrant; oral SERDs where available).
StandardCurated
Capivasertib + fulvestrant improves outcomes in tumors with PI3K/AKT/PTEN alterations
Capivasertib + fulvestrant improves outcomes in tumors with PI3K/AKT/PTEN alterations; counsel on diarrhea, rash, and hyperglycemia.
StandardCurated
Everolimus + exemestane restores endocrine sensitivity in some AI-resistant HR+
Everolimus + exemestane restores endocrine sensitivity in some AI-resistant HR+; prevent stomatitis with dexamethasone mouthwash.
StandardCurated
Adjuvant abemaciclib for high-risk node-positive HR+/HER2– improves IDFS when added to endocrine therapy (strict eligibility)
Adjuvant abemaciclib for high-risk node-positive HR+/HER2– improves IDFS when added to endocrine therapy (strict eligibility).
AdjuvantStandardCurated
Later-line ADCs in HR+/HER2–: sacituzumab govitecan after endocrine + targeted therapies
Later-line ADCs in HR+/HER2–: sacituzumab govitecan after endocrine + targeted therapies; manage neutropenia/diarrhea proactively.
StandardCurated
anastrozole
FDA-approved for this cancer.
Guideline option
tamoxifen
FDA-approved for this cancer.
Guideline option

Established care shown from OncoForge editorial curation · reviewed September 15, 2025 — authoritative citations (NCI PDQ / FDA) are being added.

Supportive care (18)
  • Lymphedema program: prehab education, early PT/OT, compression fitting, and progressive weight training; prompt eval for arm swelling/tightness or axillary web syndrome.
  • Shoulder mobility & scar management: early ROM, myofascial techniques, and desensitization to prevent frozen shoulder and chronic pain.
  • Menopause symptom toolkit on endocrine therapy: non-hormonal options (SSRIs/SNRIs, gabapentin, clonidine), vaginal moisturizers/lubricants, and pelvic floor therapy; consider low-dose vaginal estrogen only after oncology review.
  • Sexual health: address dyspareunia, libido, and body image; consider specialized pelvic PT and counseling.
  • AI bone program: weight-bearing/resistance exercise, vitamin D/calcium, baseline and periodic DEXA; consider adjuvant bisphosphonates (postmenopausal) or denosumab with dental clearance.
  • Cardio-oncology: manage BP, lipids, diabetes; baseline CV risk assessment before anthracyclines/HER2 therapy; lifestyle coaching for activity, weight, and sleep.
  • Return-to-work & cognitive rehab: graded return plan, fatigue pacing, occupational therapy, and ‘chemo-brain’ strategies (sleep hygiene, cognitive exercises).
  • Alopecia and neuropathy mitigation: scalp cooling during sensitive chemo; frozen gloves/booties during taxanes to reduce CIPN and nail toxicity.
  • Stomatitis prevention: steroid mouthwash with everolimus; salt/bicarbonate rinses broadly; early dental issues triage to avoid ONJ when on bone agents.
  • GI playbooks: diarrhea (abemaciclib/capecitabine/sacituzumab) start loperamide early; nausea bundles with evidence-based antiemetics; constipation prevention with opioids/antiemetics.
  • Pulmonary vigilance: new cough/dyspnea/fever on T-DXd or everolimus → urgent ILD/pneumonitis evaluation and drug hold.
  • Dermatologic care: alpelisib/capivasertib rash prophylaxis (non-sedating antihistamines), urea-based emollients; HFS care on capecitabine.
  • Metabolic monitoring: proactive glucose/A1c and dietitian input with alpelisib/capivasertib; avoid unsupervised fasting in underweight/sarcopenic patients.
  • Multimodal analgesia: NSAIDs/acetaminophen, neuropathic agents (duloxetine for CIPN), interventional options when needed; early palliative/supportive care improves QoL.
  • Sleep, anxiety, and mood: CBT-I, mindfulness, exercise; screen for depression/PTSD and treat promptly.
  • Vaccination plan: inactivated vaccines per guidelines; avoid live vaccines during cytotoxic therapy/biologics; consider HBV screening in at-risk patients.
  • Port care: educate on infection/DVT signs; coordinate holds around procedures (anticoagulants, bone agents).
  • Navigation and financial counseling: transportation, work leave, medication access, and clinical trial matching to reduce care gaps.
Investigational & adjunct compounds — detail (75)
Meta-analysis (29)
Acetyl-L-carnitineacupressureacupuncturealoe veraAromatase inhibitorsAromatase inhibitors· Adjuvant (after surgery)axillary lymph node dissection (ALND)bone-modifying agentsbreast-conserving surgery (BCS)endocrine therapyendocrine therapy· First-line (advanced disease)gingerginsengGonadotrophin-releasing hormone agonists (GnRHa)Hippocampal avoidanceimmediate breast reconstruction (lumpectomy reconstruction)mastectomyMemantineoff-labelradiation therapy (RT)· Adjuvant (after surgery)re-excisionregional nodal irradiation (RNI)sentinel lymph node biopsy (SLNB)· Neoadjuvant (before surgery) · hormone receptor-positive, human epidermal growth factor receptor 2-negativesentinel lymph node biopsy (SLNB)sperm, oocyte, and embryo cryopreservationStereotactic radiosurgerySurgerytargeted systemic therapyWhole-brain radiotherapywhole-breast radiation therapy (whole-breast RT)
Named in the literature
estrogen therapy / hormone therapy (ET/HT)Primary endocrine therapyAdjuvant systemic therapy· Adjuvant (after surgery)Bone-modifying drugsNeoadjuvant systemic treatment options· Neoadjuvant (before surgery)Supportive carebreast MRI (diagnostic)breast MRI (screening)breast ultrasound (diagnostic)Breath-hold techniques (e.g., deep-inspiration breath hold)diagnostic mammography and tomosynthesismammography and digital breast tomosynthesismammography (male screening)Oncoplastic Breast Surgerysurgical resectionAccelerated partial breast irradiation (APBI)Hypofractionated whole-breast irradiationintraoperative radiation therapyIntraoperative radiotherapypostmastectomy radiation therapy (PMRT)· First-line (advanced disease)postmastectomy radiation therapy (PMRT)· Neoadjuvant (before surgery)postmastectomy radiation therapy (PMRT)Postmastectomy radiotherapy (PMRT) to chest wall and supraclavicular nodesRadiotherapyRegional nodal irradiation (supraclavicular)Single-fraction radiotherapy (8 Gy) for bone metastasesstereotactic ablative body radiotherapy (SBRT)Boost dose over the tumour bedcapivasertibCDK4/6 inhibitorsPIK3CA inhibitorsTargeted therapiesAxillary irradiation?anti-HER2 therapy· Maintenance · biomarker-selectedbilateral risk-reducing mastectomy (BRRM)· CDH1 pathogenic variant carriersOvarian suppressionImmunotherapeutic agentRisk-reducing bilateral salpingo-oophorectomy· pathogenic germline variant in the BRCA1, BRCA2, and other ovarian cancer-associated genesexemestaneraloxifeneAromatase inhibitors· First-line (advanced disease) · estrogen receptor-positivebisphosphonateszoledronic aciddenosumab· Adjuvant (after surgery)
Lab / animal only

"Tested in people" rows show the highest trial phase found in that compound's cited human studies (Phase I–IV; "phase not reported" = a human study with no phase tag). "Studied" = named in the cited literature for this cancer. "FDA ✓" = FDA-approved for this cancer; "off-label" = an FDA-approved drug used outside its approved indications (per openFDA). Not a claim that anything works.

Reported figures

Get cited updates on Breast Invasive Ductal Carcinoma (IDC)
A monthly email when the research changes — $10/mo. Manage follows
Follow Breast Invasive Ductal Carcinoma (IDC)

Snapshot

The essentials in ~60 seconds — every line is drawn from the cited sources below.

What it is
Invasive ductal breast cancer is a common type of breast cancer that often presents as a new palpable breast mass (breast pain is rarely associated); screening detects many cancers earlier and reduces mortality. [1][2][3][4]
Survival
Advanced/metastatic breast cancer is described as virtually incurable with a median overall survival of about 3 years and a 5-year survival rate of around 25%; survival has improved in some subgroups (for example, median overall survival is now five or more years in patients with HER2-positive disease and those with estrogen-positive/HER2-negative advanced breast cancer). [5][6]
Standard treatment
Care is multidisciplinary (surgery, radiation, medical oncology) with whole‑breast irradiation standard after breast‑conserving surgery for stage I–II disease and radiotherapy standard after breast‑conserving surgery for DCIS; aromatase inhibitors are recommended as first‑line standard of care for postmenopausal estrogen receptor–positive disease. [7][8][9][10]
Key test
Key tests at diagnosis include HER2 testing (IHC/ISH) to define HER2 status and BRCA1/2 germline testing (offered to all newly diagnosed patients ≤65 years and select patients >65) because results affect management; the 21‑gene recurrence score is used to inform the choice of endocrine therapy alone versus adding chemotherapy. [11][12][13][14]
Biggest challenge
The main clinical challenges are advanced/metastatic disease with limited long‑term survival and many unanswered questions about optimal management, together with heterogeneity of disease and insufficient evidence for some populations (for example older adults). [5][6][15]

Ask about Breast Invasive Ductal Carcinoma (IDC)

Answers come only from the cited sources on this page — with the supporting evidence shown. If the sources here don't cover your question, it will say so. Educational information, not medical advice.

Key numbers & factors

Risk factors

  • increases riskBRCA1 pathogenic variantlifetime breast cancer risk 50–85% [16]
  • increases riskBRCA2 pathogenic variantlifetime breast cancer risk 45–69% [16]
  • increases riskPrior mantle radiation between ages 10–30 [17]
  • increases riskGenetic predisposition (family history/affected relative)earlier screening recommended (annual mammography beginning 10 years earlier than affected relative but not before age 30) [17]
  • increases riskDelayed childbearing (older maternal age)pregnancy‑associated breast cancer (PABC) is increasing as more women delay child bearing [18]
  • increases riskIncreasing age (older adults)breast cancer is increasingly prevalent in older adults [15]
  • increases riskNon‑Hispanic White race/ethnicityhighest incidence among US women [19]
  • increases riskNon‑Hispanic Black race/ethnicityhighest mortality rate among US women [19]
  • lowers riskRisk‑reducing bilateral salpingo‑oophorectomy in women predisposed to HBOCrisk reduction of up to 90% in women predisposed to HBOC [20]

Biomarkers

  • BRCA1/BRCA2 (germline)Actionableidentify hereditary risk and select patients for BRCA‑directed management/PARP inhibitor eligibility [16][13][21]
  • HER2 (IHC/ISH)Actionabledetermine HER2 status to guide HER2‑directed therapy decisions [11][12]
  • 21‑gene recurrence score (gene expression assay)Actionableinform assignment to endocrine therapy alone versus adding chemotherapy [14]
  • ESR1 mutation · used in defining secondary endocrine resistance [6]
  • PALB2, RAD51C, RAD51D, TP53 (panel genes) · included on multigene panels to assess hereditary susceptibility [21]

10 sections — tap any heading to expand its cited detail. Key points are above.

Overview12 points

Key figures

Survival & outcomes
OutcomeValue95% CI
median overall survival (OS)3
5-year survival rate25%
Source quotes
  • Advanced/metastatic breast cancer remains a virtually incurable disease, with a median overall survival (OS) of about 3 years and a 5-year survival rate of around 25%,3 , 4 even in countries without major accessibility problems.
  • Guideline recommendations have been updated, including an ESO-ESMO international consensus update for the management of breast cancer in young women (updated from BCY4), and guideline authors recommend a low threshold for brain MRI and appropriate local and systemic therapy for patients with brain metastases from HER2-positive advanced breast cancer. [22][23]
  • A new palpable breast mass is a common presenting sign of breast cancer, while breast pain is rarely associated with breast cancer. [1][2]
  • Advanced/metastatic breast cancer is described as virtually incurable with a median overall survival of about 3 years and a 5-year survival rate of around 25%. [5]
  • An updated clinical practice guideline provides recommendations on the use of postmastectomy radiation therapy (PMRT) in breast cancer treatment. [24]
  • Routine screening is stated to substantially reduce the risk of mortality and morbidity of breast cancer through early detection. [3]
  • Metastases from invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) have different preferential tropisms and target organs in their metastatic spread, as well as different metabolic behaviors, resulting in dedicated imaging strategies. [6]
  • Guideline authors state that the role of imaging for staging and surveillance purposes should be determined based on evidence-based guidelines; in asymptomatic patients who received treatment with curative intent, there is no role for imaging to screen for distant recurrence. Routine surveillance with an annual 2-D mammogram and/or tomosynthesis is recommended to detect an in-breast recurrence or a new primary breast cancer in women with a history of breast cancer, and MRI is increasingly used as an additional screening tool in women with a history of breast cancer, especially in women with dense breasts. [25]
  • Whole-breast irradiation (WBI) is the standard treatment following breast-conserving surgery (BCS) for patients with stage I–II breast cancer, and radiotherapy (RT) is the standard treatment for ductal carcinoma in situ (DCIS) after breast-conserving surgery. [8]
  • Management of breast cancer in older adults is challenging because the disease is highly heterogeneous and there is insufficient evidence specific to older adults; decision making should not be driven by age alone but should involve geriatric assessments plus careful consideration of life expectancy, competing risks of mortality, and patient preferences. [15]
  • Many management approaches used for men with breast cancer are similar to those used for women. [26]
  • Immediate breast reconstruction (IBR) rates after mastectomy are increasing. [27]
  • Breast cancer is the most commonly diagnosed cancer in women in the United States and the second leading cause of cancer death in American women. [4]
Epidemiology9 points

Key figures

Survival & outcomes
OutcomeValue95% CI
proportion of diagnosed breast cancer that is DCIS20%
Source quotes
  • Ductal carcinoma in situ (DCIS) accounts for approximately 20% of diagnosed breast cancer.
  • Sources report that ductal carcinoma in situ accounts for approximately 20% of diagnosed breast cancer. [28][29]
  • Breast pain is a common symptom, experienced by up to 80% of women at some point in their lives. [2]
  • More than 2 million women are diagnosed with breast cancer worldwide every year, and the estimated 5-year prevalence is almost 8 million cases. [16]
  • In Europe, about 13% of women will be diagnosed with breast cancer during their lifetime; about 3% of women will eventually die from breast cancer; the estimated number of deaths for breast cancer in Europe in 2020 was about 140,000 women. [16]
  • Guideline authors state that early detection of breast cancer from regular screening substantially reduces breast cancer mortality and morbidity. [30]
  • Among all US women, breast cancer is the second most common cancer and the second most common cause of cancer death; Non-Hispanic White women have the highest incidence of breast cancer and non-Hispanic Black women have the highest mortality rate. [19]
  • The USPSTF recommends biennial screening mammography for women aged 40 to 74 years. [19]
  • Breast cancer is increasingly prevalent in older adults and is a substantial part of routine oncology practice. [15]
  • Pregnancy-associated breast cancer (PABC) is increasing as more women delay child bearing into the fourth decade of life. [18]
Key biomarkers13 points
  • The guidelines were expanded to include genetic screening. [15][29]
  • HER2 testing guidance defines IHC 2+ as invasive breast cancer with weak to moderate complete membrane staining observed in >10% of tumor cells, allows a new HER2 test on the excision specimen when an initial core needle biopsy result is negative based on specific clinical criteria, and recommends more rigorous interpretation criteria for ISH with concomitant IHC review for dual-probe ISH groups 2 to 4 to determine HER2 status. [11][12]
  • The ASCO guideline identifies 'hormone receptor-positive, human epidermal growth factor receptor 2-negative' disease as part of the criteria for select patients in whom routine sentinel lymph node biopsy (SLNB) should not be recommended. [31]
  • The ESMO Precision Oncology Working Group judged six breast cancer susceptibility genes (BRCA1, BRCA2, PALB2, RAD51C, RAD51D and TP53 for breast cancer diagnosed <40 years) as of high or moderate impact for inclusion on multigene panels. [21]
  • BRCA1 and BRCA2 are associated with lifetime breast cancer risks of 50–85% and 45–69%, respectively. [16]
  • BRCA1/2 mutation testing should be offered to all newly diagnosed patients with breast cancer ≤65 years and to select patients >65 years based on personal history, family history, ancestry, or eligibility for PARP inhibitor therapy. [13]
  • The ESMO Precision Medicine Working Group recommends running tumour next-generation sequencing (NGS) in patients with advanced breast cancer. [32]
  • The guidelines were expanded to include gene expression profiles. [15]
  • The 2018 publication of the TAILORx trial helped refine the use of genetic expression assays, specifically the 21-gene recurrence score, in assigning patients to endocrine therapy alone or with chemotherapy. [14]
  • No tests are currently used for tumor radiosensitivity prediction, although the radiosensitivity index and the genome-based model for adjusting radiotherapy dose assays seem the most promising with level II evidence. [33]
  • Germline CDH1 pathogenic variants are reported to be associated with lobular breast cancer but not with invasive ductal carcinoma (invasive breast carcinoma of no special type). [34]
  • Aromatase inhibitors are recommended as the first-line standard of care for postmenopausal estrogen receptor-positive breast cancer. [10]
Show 1 lab & early-research finding
  • Single nucleotide polymorphisms and radiation-induced CD8 T-lymphocyte apoptosis assays are reported as having level I evidence for predicting normal tissue radiosensitivity. [33]
Standard management34 points

Key figures

Survival & outcomes
OutcomeValue95% CI
margin width2
Source quotes
  • In patients undergoing BCS or mastectomy, a margin width of at least 2 mm is optimal to minimize the risk of local recurrence (LR).
  • Breast cancer care is managed by a multidisciplinary team including surgical oncology, radiation oncology, and medical oncology; oncoplastic breast surgery has become standard of care and guidelines provide MDT guidance on oncoplastic and reconstructive practice at each stage of a patient's journey. [7][35]
  • Sources state that mammography remains the only validated screening tool; for average‑risk women with dense breasts, supplemental screening with contrast‑enhanced mammography, screening ultrasound, breast MRI, or abbreviated breast MRI may be considered; there is strong evidence supporting screening high‑risk women with breast MRI regardless of breast density; in men with a history of breast cancer, breast MRI is not recommended routinely. [36][26]
  • The Ontario Health (Cancer Care Ontario) guideline for DCIS recommends that women who are candidates for breast-conserving surgery (BCS) should be offered the choice of BCS or mastectomy with the option of reconstruction; when BCS is performed all mammographically suspicious calcifications should be removed and margins should be microscopically cleared of DCIS, a margin width of at least 2 mm is stated as optimal to minimize the risk of local recurrence, routine additional surgery may not be warranted in patients with negative margins (at least 2 mm) who are undergoing radiation therapy, and active surveillance is an area of ongoing investigation and is not a standard option currently. [29]
  • The ASCO guideline update addresses the use of sentinel lymph node biopsy (SLNB) in patients with early-stage breast cancer treated with initial surgery. [31]
  • For women who have completed breast conservation therapy for DCIS, routine surveillance with annual mammography and/or tomosynthesis is recommended to detect in‑breast recurrence or a new primary breast cancer. [28]
  • Currently, available data does not support the impact of local therapies on overall survival, therefore it cannot be recommended in routine clinical practice. [6]
  • Partial breast irradiation delivered using 3-dimensional conformal radiation therapy, intensity modulated radiation therapy, multicatheter brachytherapy, and single-entry brachytherapy results in similar ipsilateral breast recurrence (IBR) as whole breast irradiation with long-term follow-up. [37]
  • Hypofractionated whole-breast irradiation (WBI) is recommended as an equivalent treatment to conventionally fractionated WBI and is recommended in all cases after considering dose homogeneity and dose to normal tissues. [8]
  • Tumor bed boost irradiation is weakly recommended for patients with pathologically negative margins after breast-conserving surgery for invasive breast cancer, particularly in younger patients. [8]
  • Regional nodal irradiation (RNI) to the ipsilateral supraclavicular node is the standard treatment for patients with ≥ 4 positive axillary nodes after breast-conserving surgery, and postmastectomy radiotherapy (PMRT) is the standard treatment for patients with ≥ 4 positive axillary nodes after mastectomy. [8]
  • Radiotherapy should be initiated within 20 weeks of surgery in patients who do not receive postoperative chemotherapy, and chemotherapy should be completed before radiotherapy in patients requiring postoperative chemotherapy. [8]
  • The Japanese Breast Cancer Society guideline states that its primary aim is to provide evidence-based recommendations to empower patients and healthcare professionals in making informed decisions regarding surgical treatment for breast cancer. [38]
  • Guideline recommendations were updated on geriatric assessment, ductal carcinoma in situ, screening, primary endocrine therapy, surgery, radiotherapy, adjuvant systemic therapy, and secondary breast cancer. [15]
  • Ipsilateral annual mammogram should be offered to men with a history of breast cancer treated with lumpectomy, and contralateral annual mammogram may be offered to men with a history of breast cancer and a genetic predisposing mutation. [26]
  • Genetic counseling and germline genetic testing of cancer predisposition genes should be offered to all men with breast cancer. [26]
  • A short diagnostic delay (for example 6–12 weeks) should not affect overall outcomes, while a diagnostic delay longer than 3 months potentially does. [39]
  • The Panel recommends that women with node-positive breast cancer receive extended therapy, including an AI, for up to a total of 10 years of adjuvant endocrine treatment; many women with node-negative breast cancer should consider extended therapy for up to a total of 10 years of adjuvant endocrine treatment based on considerations of recurrence risk using established prognostic factors; the Panel noted that the benefits in absolute risk of reduction were modest and that, for lower-risk node-negative or limited node-positive cancers, an individualized approach to treatment duration that is based on considerations of risk reduction and tolerability was appropriate; bone-related toxic effects were more common with extended AI treatment. [40]
  • Ovarian suppression has been validated as the optimal approach in higher risk premenopausal women, based on updated analysis of the SOFT and TEXT pivotal trials. [14]
  • In the metastatic setting, the NCCN Guidelines further reinforce the benefit of the CDK4/6 inhibitors, extending the "preferred" recommendation to all the available agents in metastatic disease. [14]
  • Options in triple-negative breast cancer now include, for the first time, an immunotherapeutic agent. [14]
  • Postmastectomy radiation therapy (PMRT) contouring guidelines for target volumes in the setting of implant-based immediate breast reconstruction (IBR) are lacking; this paper aims to describe delineation guidelines for PMRT after implant-based IBR based on a thorough understanding of the surgical procedures, disease stage, patterns of recurrence and radiation techniques. [27]
  • We may expect a risk reduction of up to 90% in women predisposed to HBOC who undergo risk-reducing bilateral salpingo-oophorectomy. [20]
  • The goal for management of ductal carcinoma in situ (DCIS) is to prevent the development of invasive breast cancer. [9]
  • Health care providers should initiate the discussion on the possibility of infertility with patients with cancer treated during their reproductive years as early as possible. [41]
  • Sperm, oocyte, and embryo cryopreservation are considered standard practice and are widely available. [41]
  • There is conflicting evidence to recommend gonadotrophin-releasing hormone agonists (GnRHa) and other means of ovarian suppression for fertility preservation. [41]
  • Any woman presenting with a palpable lesion should have a thorough clinical breast examination, and imaging evaluation is necessary in almost all cases to characterize the palpable lesion. [1]
  • When a suspicious finding is identified, biopsy is indicated. [1]
  • A careful baseline evaluation is needed of the risk of fracture in postmenopausal women about to start treatment with AIs but also in all premenopausal women with early disease. [10]
  • Imaging evaluation is usually not indicated if breast pain is cyclic or nonfocal. [2]
  • For focal, noncyclic breast pain, imaging may be appropriate mainly for reassurance and to identify treatable causes; ultrasound can be the initial examination used to evaluate women under 30, while for women 30 and older diagnostic mammography, digital breast tomosynthesis, and ultrasound may all serve as appropriate initial examinations. [2]
  • For intermediate-risk women, ultrasound or MRI may be indicated as an adjunct to mammography depending upon specific risk factors. [17]
  • For women at high risk due to prior mantle radiation between the ages of 10 to 30, mammography is recommended starting 8 years after radiation therapy but not before age 25. [17]
  • For women with a genetic predisposition, annual screening mammography is recommended beginning 10 years earlier than the affected relative at the time of diagnosis but not before age 30. [17]
Treatments & compounds studied79 treatments

Targeted therapy

  • capivasertib: The ABC guidelines included additional statements on capivasertib developed after the ABC 7 conference. [6]
    median time until progression not amenable to further SBRT 10.4 months
    Source quote
    • Of note, in patients with prior clinical benefit from CDK4/6 inhibitor plus aromatase inhibitors (AI), the possibility to delay a change in systemic therapy by use of SBRT, including the possibility of subsequent SBRT, for up to 5 sites of oligo-progressive disease was investigated in the AVATAR phase 2 trial (n = 32) with a median time until progression not amenable to further SBRT of 10.4 months [28].
  • CDK4/6 inhibitors · 2 findings
    • The ABC guidelines note that adjunctive drugs such as CDK4/6 inhibitors are considered adjunctive and that their use does not contribute to or affect the definitions of endocrine sensitivity. [6]
      median time until progression not amenable to further SBRT 10.4 months
      Source quote
      • Of note, in patients with prior clinical benefit from CDK4/6 inhibitor plus aromatase inhibitors (AI), the possibility to delay a change in systemic therapy by use of SBRT, including the possibility of subsequent SBRT, for up to 5 sites of oligo-progressive disease was investigated in the AVATAR phase 2 trial (n = 32) with a median time until progression not amenable to further SBRT of 10.4 months [28].
    • CDK4/6 inhibitors are presented as preferred agents in the metastatic setting by the NCCN Guidelines. [14]
  • PIK3CA inhibitors: The ABC guidelines note that adjunctive drugs such as PIK3CA inhibitors are considered adjunctive and that their use does not contribute to or affect the definitions of endocrine sensitivity. [6]
    median time until progression not amenable to further SBRT 10.4 months
    Source quote
    • Of note, in patients with prior clinical benefit from CDK4/6 inhibitor plus aromatase inhibitors (AI), the possibility to delay a change in systemic therapy by use of SBRT, including the possibility of subsequent SBRT, for up to 5 sites of oligo-progressive disease was investigated in the AVATAR phase 2 trial (n = 32) with a median time until progression not amenable to further SBRT of 10.4 months [28].
  • Targeted therapies: The guidelines were expanded to include targeted therapies. [15]
  • targeted systemic therapy: Targeted systemic therapy may be used to treat advanced or metastatic disease in men using the same indications and combinations offered to women. [26]
  • anti-HER2 therapy: Maintenance · biomarker-selectedMaintenance therapy in advanced breast cancer can include the continuation of anti-HER2 therapy and/or endocrine therapy after discontinuation of chemotherapy. [5]
  • denosumab: Adjuvant (after surgery)The anti-RANK ligand antibody denosumab is reported as an emerging adjuvant option to prevent AI-induced bone loss and has been shown to extend the time to first fracture in postmenopausal women treated with AIs. [10]

Immunotherapy

  • Immunotherapeutic agent: An immunotherapeutic agent is included among options for triple-negative breast cancer. [14]

Hormonal therapy

  • endocrine therapy · 2 findings
    • Hormonal (endocrine) therapy is noted as an area of new evidence and consideration in the management landscape. [29]
    • First-line (advanced disease)Men with advanced or metastatic disease should be offered endocrine therapy as first-line therapy except in cases of visceral crisis or rapidly progressive disease. [26]
  • estrogen therapy / hormone therapy (ET/HT): Estrogen therapy (ET) or combined estro-progestin hormone therapy (HT) can be used with great caution in women after estrogen receptor (ER)/progesterone receptor (PR)-positive breast cancer. [42]
  • Primary endocrine therapy: Recommendations on primary endocrine therapy were updated. [15]
  • Aromatase inhibitors · 3 findings
    • Extended aromatase inhibitor (AI) therapy for up to 10 years is recommended for women with node-positive breast cancer. [40]
    • Adjuvant (after surgery)Many women with node-negative breast cancer should consider extended aromatase inhibitor (AI) therapy for up to a total of 10 years of adjuvant endocrine treatment based on recurrence-risk considerations. [40]
    • First-line (advanced disease) · estrogen receptor-positiveAromatase inhibitors are described as the first-line recommended standard of care for postmenopausal estrogen receptor-positive breast cancer. [10]
  • Ovarian suppression: Ovarian suppression is validated as the optimal approach in higher risk premenopausal women. [14]
  • anastrozole: Anastrozole is listed among endocrine therapy options for breast cancer risk reduction in postmenopausal women at increased risk. [43]
  • exemestane: Exemestane is listed among endocrine therapy options for breast cancer risk reduction in postmenopausal women at increased risk. [43]
  • raloxifene: Raloxifene is listed among endocrine therapy options for breast cancer risk reduction in postmenopausal women at increased risk. [43]
  • tamoxifen: Tamoxifen is listed among endocrine therapy options for breast cancer risk reduction in postmenopausal women at increased risk. [43]
  • Gonadotrophin-releasing hormone agonists (GnRHa): Gonadotrophin-releasing hormone agonists (GnRHa) may be offered to young women with breast cancer, when proven fertility preservation methods are not feasible, to reduce the likelihood of chemotherapy-induced ovarian insufficiency. [41]

Radiotherapy

  • Accelerated partial breast irradiation (APBI): Accelerated partial breast irradiation (APBI) was associated with a significantly higher local recurrence rate than whole-breast irradiation in a meta-analysis (RR 1.81, 95% CI 1.16–2.84, p = 0.009). [8]
  • Hypofractionated whole-breast irradiation: Hypofractionated whole-breast irradiation (hypofractionated WBI) is recommended as an equivalent alternative to conventionally fractionated WBI, with no significant difference in local recurrence (RR 0.94, 95% CI 0.79–1.11) or overall survival (HR 0.92, 95% CI 0.82–1.04). [8]
  • intraoperative radiation therapy: Intraoperative radiation therapy alone is associated with a higher ipsilateral breast recurrence (IBR) rate compared with whole breast irradiation in patients with early-stage invasive breast cancer or ductal carcinoma in situ. [37]
  • Intraoperative radiotherapy: Intraoperative radiotherapy (a form of APBI) was associated with a significantly higher local recurrence rate than whole-breast irradiation (RR 3.38, 95% CI 2.14–5.35, p < 0.00001) in a meta-analysis subgroup. [8]
  • postmastectomy radiation therapy (PMRT) · 4 findings
    • First-line (advanced disease)After upfront mastectomy, postmastectomy radiation therapy (PMRT) is indicated for most patients with node-positive breast cancer and select patients with node-negative disease. [24]
    • Neoadjuvant (before surgery)PMRT is recommended after neoadjuvant systemic therapy for patients presenting with locally advanced disease and for those with residual nodal disease at the time of surgery. [24]
    • When PMRT is delivered, treatment to the ipsilateral chest wall or reconstructed breast and regional lymphatics is recommended, with moderate hypofractionation preferred. [24]
    • A consensus endorsed by a global multidisciplinary group described delineation guidelines for PMRT after implant‑based immediate breast reconstruction. [27]
  • Postmastectomy radiotherapy (PMRT) to chest wall and supraclavicular nodes: Irradiation to the chest wall and supraclavicular lymph nodes is the standard recommended target for postmastectomy radiotherapy (PMRT). [8]
  • radiation therapy (RT): Adjuvant (after surgery)The guideline includes recommendations for the primary treatment of DCIS with surgical treatment and/or radiation therapy. [29]
  • Radiotherapy: Recommendations on radiotherapy were updated. [15]
  • regional nodal irradiation (RNI): Regional nodal irradiation (RNI) is described as an option to offer with postmastectomy RT in patients with clinically node‑negative invasive breast cancer ≤5 cm who receive mastectomy and have one to two positive sentinel nodes. [31]
  • Regional nodal irradiation (supraclavicular): Regional nodal irradiation (RNI) to the supraclavicular region is weakly recommended for patients with 1–3 positive axillary nodes after breast‑conserving surgery with axillary dissection. [8]
    IBTR rate (no boost) 16.4 vs 12% vs boost irradiationIBTR rate (boost) 12 vs 16.4% vs no boost
    Source quotes
    • delivering a 16-Gy boost to the tumor bed reduced the rate of ipsilateral breast tumor recurrence (IBTR) from 16.4 to 12.0% but did not improve OS
    • delivering a 16-Gy boost to the tumor bed reduced the rate of ipsilateral breast tumor recurrence (IBTR) from 16.4 to 12.0% but did not improve OS
  • Single-fraction radiotherapy (8 Gy) for bone metastases: Single‑fraction radiotherapy of 8 Gy is strongly recommended as an equivalent treatment to multifraction radiotherapy for pain relief in patients with painful bone metastases of breast cancer. [8]
    IBTR rate (no boost) 16.4 vs 12% vs boost irradiationIBTR rate (boost) 12 vs 16.4% vs no boost
    Source quotes
    • delivering a 16-Gy boost to the tumor bed reduced the rate of ipsilateral breast tumor recurrence (IBTR) from 16.4 to 12.0% but did not improve OS
    • delivering a 16-Gy boost to the tumor bed reduced the rate of ipsilateral breast tumor recurrence (IBTR) from 16.4 to 12.0% but did not improve OS
  • stereotactic ablative body radiotherapy (SBRT): In the NRG‑BR002 phase 2 trial (n = 125) comparing standard systemic therapy with or without metastasis‑directed treatments (SBRT and/or surgical resection), the ablative arm had new metastases inside the index area in 7% compared to 29% for standard of care. [6]
    median time until progression not amenable to further SBRT 10.4 months
    Source quote
    • Of note, in patients with prior clinical benefit from CDK4/6 inhibitor plus aromatase inhibitors (AI), the possibility to delay a change in systemic therapy by use of SBRT, including the possibility of subsequent SBRT, for up to 5 sites of oligo-progressive disease was investigated in the AVATAR phase 2 trial (n = 32) with a median time until progression not amenable to further SBRT of 10.4 months [28].
  • Stereotactic radiosurgery (SRS) for limited brain metastases: After stereotactic radiosurgery (SRS) for 1–4 brain metastases measuring < 3 cm, it is weakly recommended not to add whole‑brain irradiation. [8]
    IBTR rate (no boost) 16.4 vs 12% vs boost irradiationIBTR rate (boost) 12 vs 16.4% vs no boost
    Source quotes
    • delivering a 16-Gy boost to the tumor bed reduced the rate of ipsilateral breast tumor recurrence (IBTR) from 16.4 to 12.0% but did not improve OS
    • delivering a 16-Gy boost to the tumor bed reduced the rate of ipsilateral breast tumor recurrence (IBTR) from 16.4 to 12.0% but did not improve OS
  • Boost dose over the tumour bed: A boost dose over the tumour bed is required for patients younger than 50 years old. [44]
  • whole-breast radiation therapy (whole-breast RT): The SLNB guideline specifies whole‑breast radiation therapy with or without RNI as the radiation context in which ALND is not recommended for patients with one or two sentinel lymph node metastases who will receive breast‑conserving surgery and whole‑breast RT with or without RNI. [31]
  • Whole-brain radiotherapy: Whole-brain radiotherapy is listed as a local therapy option for patients with brain metastases. [23]
  • Stereotactic radiosurgery: Stereotactic radiosurgery is listed as a local therapy option for patients with brain metastases. [23]
  • Hippocampal avoidance: Hippocampal avoidance is recommended to be added to whole-brain radiotherapy when possible for patients with brain metastases. [23]
  • Axillary irradiation: Axillary irradiation is recommended only when there is no axillary surgical dissection and a positive sentinel lymph node. [44]

Repurposed drugs

  • Memantine: Memantine is recommended to be added to whole-brain radiotherapy when possible for patients with brain metastases. [23]
  • bisphosphonates: Bisphosphonates have been shown in several phase III trials to prevent cancer treatment–induced bone loss, although no fracture data were available. [10]
  • zoledronic acid: Recent data suggest that bisphosphonates, especially intravenous zoledronic acid, may reduce bone recurrence as well as extra-skeletal metastasis and breast cancer mortality in postmenopausal women. [10]

Supplements & natural agents

  • aloe vera: Aloe vera gel is typically used with the goal of healing surgical wounds or preventing or treating radiation-induced dermatitis in oncology patients. [45]
  • ginger: Ginger has been studied for the treatment of chemotherapy-induced nausea and vomiting in cancer patients. [45]
  • ginseng: Ginseng is often used as an herbal supplement to address cancer-related fatigue. [45]
  • Acetyl-L-carnitine: Acetyl-L-carnitine is a dietary supplement that some patients use to address cancer-related fatigue. [45]

Procedures & devices

  • axillary lymph node dissection (ALND): Clinicians may offer postmastectomy radiation with regional nodal irradiation (RNI) and omit axillary lymph node dissection (ALND) in patients with clinically node‑negative invasive breast cancer ≤5 cm who receive mastectomy and have one to two positive sentinel nodes. [31]
  • breast-conserving surgery (BCS): Breast-conserving surgery (BCS) is offered as one surgical option and patients who are candidates for BCS should be offered the choice of BCS or mastectomy with the option of reconstruction. [29]
  • breast MRI (diagnostic): Breast MRI is described as an appropriate complementary examination for initial imaging in a new diagnosis of DCIS. [28]
  • breast MRI (screening): In high-risk patients, screening with breast MRI is recommended starting as early as 25 to 30 years of age. [3]
  • breast ultrasound (diagnostic): Breast ultrasound is described as an appropriate complementary examination for initial imaging in a new diagnosis of DCIS. [28]
  • Breath-hold techniques (e.g., deep-inspiration breath hold): Breath-hold techniques (such as deep-inspiration breath hold) are increasingly used in radiotherapy and the guideline reviews equipment, staff training, patient coaching, and image guidance for breath-hold treatments, including for breast cancer. [46]
  • diagnostic mammography and tomosynthesis: Initial imaging for a new diagnosis of DCIS consists of diagnostic mammography and/or tomosynthesis, while breast ultrasound and breast MRI may be appropriate as complementary examinations. [28]
  • immediate breast reconstruction (lumpectomy reconstruction): The guideline indicates that the option of immediate lumpectomy reconstruction should be offered if a patient is deemed an appropriate candidate. [29]
  • mammography and digital breast tomosynthesis: For patients assigned female at birth with native breast tissue, mammography and digital breast tomosynthesis are recommended for breast cancer screening in all risk categories. [3]
  • mammography (male screening): For men of higher-than-average risk, screening with mammography as annual surveillance imaging is usually appropriate. [47]
  • mastectomy: Mastectomy (with the option of reconstruction) is presented as an alternative surgical option that should be offered alongside BCS for eligible patients. [29]
  • Oncoplastic Breast Surgery: Oncoplastic Breast Surgery has become standard of care in the management of Breast Cancer patients. [35]
  • re-excision: For patients with positive margins after BCS or mastectomy, the guideline recommends that re-excision should be considered as soon as information is available. [29]
  • sentinel lymph node biopsy (SLNB) · 2 findings
    • Neoadjuvant (before surgery) · hormone receptor-positive, human epidermal growth factor receptor 2-negativeClinicians should not recommend routine sentinel lymph node biopsy (SLNB) in select patients who are postmenopausal and ≥50 years of age with negative preoperative axillary ultrasound and grade 1-2, small (≤2 cm), hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer who undergo breast-conserving therapy. [31]
    • Clinicians may offer SLNB in patients who have cT3-T4c or multicentric tumors (clinically node-negative) or ductal carcinoma in situ treated with mastectomy, and in patients who are obese, male, or pregnant, or who have had prior breast or axillary surgery. [31]
  • surgical resection: Surgical resection and radiofrequency ablation (RFA) have been evaluated as metastasis-directed treatments for liver lesions. [6]
  • Surgery: Surgery is listed as a local therapy option for patients with brain metastases. [23]
  • bilateral risk-reducing mastectomy (BRRM): CDH1 pathogenic variant carriersBilateral risk-reducing mastectomy (BRRM) is presented as an option to manage lobular breast cancer (LBC) risk in CDH1 pathogenic variant carriers. [34]
  • Risk-reducing bilateral salpingo-oophorectomy: pathogenic germline variant in the BRCA1, BRCA2, and other ovarian cancer-associated genesRisk-reducing bilateral salpingo-oophorectomy may reduce risk by up to 90% in women predisposed to hereditary breast and ovarian cancer (HBOC). [20]
  • sperm, oocyte, and embryo cryopreservation: Sperm, oocyte, and embryo cryopreservation are considered standard practice and are widely available for fertility preservation. [41]
  • acupuncture: Sources recommend acupuncture for reducing chemotherapy-induced nausea and vomiting in patients with breast cancer. [45]
  • acupressure: Sources recommend acupressure for reducing chemotherapy-induced nausea and vomiting in patients with breast cancer. [45]

Other

  • Adjuvant systemic therapy: Adjuvant (after surgery)Recommendations on adjuvant systemic therapy were updated. [15]
  • Bone-modifying drugs: The guidelines were expanded to include bone-modifying drugs. [15]
  • Neoadjuvant systemic treatment options: Neoadjuvant (before surgery)The guidelines were expanded to include neoadjuvant systemic treatment options. [15]
  • Supportive care: The guidelines were expanded to include supportive care. [15]
  • bone-modifying agents: Men with early-stage disease should not be treated with bone-modifying agents to prevent recurrence but may receive them to prevent or treat osteoporosis. [26]
  • ?: Bilateral ovariectomy, continuous use of LHRH agonists, or ovarian function ablation through pelvic radiotherapy are described options to obtain adequate ovarian function suppression (OFS) in premenopausal patients with advanced breast cancer. [5]
Staging & risk4 points
  • The ACR DCIS guideline states there is no role for imaging of the axilla in patients with known DCIS with or without microinvasion. [28]
  • The ABC guidelines describe advanced breast cancer as inoperable locally advanced or metastatic disease. [6]
  • Guideline authors emphasize the importance of understanding indications for extent-of-disease evaluation and staging and note that unnecessary imaging can delay care and result in adverse outcomes. [25]
  • Diagnostic breast imaging during pregnancy should be obtained to evaluate clinical symptoms and for loco-regional staging of newly diagnosed pregnancy-associated breast cancer (PABC). [18]
Prognosis6 points
  • A screening guideline states that routine screening substantially reduces the risk of mortality and morbidity of breast cancer with early detection. [3]
  • Important advances have occurred leading to an increase in the median overall survival from 2–3 years in the early 2000s to five or more years in patients with HER2-positive disease and those with estrogen-positive/HER2-negative advanced breast cancer. [6]
  • Adjuvant radiotherapy after conservative (breast‑conserving) surgery is associated with decreased rates of local recurrence and decreased disease-specific mortality. [44]
  • Visceral crisis is defined as severe organ dysfunction and is estimated to occur in only around 10%–15% of first-line advanced breast cancer cases; it indicates the need for therapies with the most rapid clinical onset. [5]
  • Extension of aromatase inhibitor (AI) treatment beyond 5 years was not associated with an overall survival advantage but was significantly associated with lower risks of breast cancer recurrence and contralateral breast cancer compared with placebo. [40]
  • There are very few adequately powered randomized controlled trials examining the effect of integrative therapies on breast cancer recurrence and survival endpoints. [45]
Safety & interactions12 points
  • Deep inspiration breath‑hold techniques are recommended to spare normal tissues when delivering postmastectomy radiotherapy (PMRT). [24]
  • The SABR-COMET trial showed long-term benefit in overall survival and progression-free survival but at the cost of more toxicity. [6]
  • Endocrine (hormone) therapy can be used with great caution after ER/PR-positive breast cancer, reflecting concerns about recurrence risk. [42]
  • Providers should offer sexual health information to breast cancer patients across the continuum of care, initiate conversations when appropriate, and refer patients to sexual medicine specialists and/or psychosocial support whenever appropriate. [48]
  • Concurrent chemoradiotherapy should be avoided in patients in adjuvant settings. [8]
  • Anti-HER2 therapy may be administered concurrently with radiotherapy, but patients with left-sided breast cancer should be carefully monitored to prevent adverse cardiac events. [8]
  • The Italian College of Breast Radiologists recommends precautions to protect patients and healthcare workers from infection or disease spread during breast imaging procedures in the COVID‑19 pandemic. [39]
  • Bone-related toxic effects were more common with extended AI treatment. [40]
  • Clinicians should not prescribe anastrozole, exemestane, or raloxifene for breast cancer risk reduction to premenopausal women. [43]
  • Mammography is safe during pregnancy. [18]
  • Several guidelines recommend considering treatment in women with a T-score ≤-2 or those with two or more clinical risk factors. [10]
  • Ginger supplementation should not be used in perioperative settings or in patients with bleeding disorders due to potential risk for increased bleeding. [45]
Biology & pathways3 points
  • The ABC guidelines include known ESR1 mutation in the definition of secondary endocrine resistance. [6]
  • CDH1 encodes E-cadherin, a transmembrane protein localised to adherens junctions with roles in cell–cell adhesion, tension sensing, and signal transduction. [34]
  • The anti-RANK ligand antibody denosumab is emerging as a new adjuvant therapeutic option to prevent AI-induced bone loss. [10]
What we don't know yet10 points
  • Several ongoing breast cancer–specific phase 3 trials will provide further data on the impact of metastasis-directed treatment on survival and determine if there are patients who may benefit. [6]
  • Ongoing clinical trials such as MyPeBS and WISDOM are investigating the implementation of different screening modalities and schedules based on personal breast cancer risk estimation. [16]
  • Active surveillance as an alternative to surgical treatment for DCIS is the subject of ongoing randomized trials and is not yet established as standard care. [29]
  • Evidence on management of breast cancer during pregnancy remains limited or conflicting and some optimal approaches are controversial. [49]
  • Many radiosensitivity assays have been developed but have not yet been included into daily clinical practice. [33]
  • There are insufficient data to recommend for or against routine brain MRI screening for brain metastases in patients with HER2-positive advanced breast cancer. [23]
  • Some clinically relevant questions in advanced breast cancer remain unanswered and may be difficult to address through traditional clinical trials. [5]
  • Shared decision making between clinicians and patients is appropriate for decisions about extended adjuvant endocrine treatment, including discussions about the absolute benefits in the reduction of breast cancer recurrence, the prevention of second breast cancers, and the impact of adverse effects of treatment. [40]
  • The field of ovarian tissue cryopreservation is advancing quickly and may evolve to become standard therapy in the future. [41]
  • The updated SIO review summarizes pertinent meta-analyses and identifies promising areas for future investigation. [45]

Sources

Every statement above is drawn from these reviewed sources. This page reports what they describe. Sources last checked June 20, 2026.

  1. GuidelineACR Appropriateness Criteria(®) Palpable Breast Masses · 2017
  2. GuidelineACR Appropriateness Criteria(®) Breast Pain · 2017
  3. GuidelineACR Appropriateness Criteria® Female Breast Cancer Screening: 2025 Update · 2025
  4. GuidelinePractice Bulletin No. 179 Summary: Breast Cancer Risk Assessment and Screening in Average-Risk Women · 2017
  5. Guideline5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) · 2020
  6. Guideline6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7) · 2024
  7. GuidelineBreast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology · 2024
  8. GuidelineThe Japanese breast cancer society clinical practice guidelines for radiation treatment of breast cancer, 2022 edition · 2024
  9. GuidelineBreast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology · 2018
  10. GuidelineOsteoporosis management in patients with breast cancer: EMAS position statement · 2017
  11. GuidelineHuman Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update · 2018
  12. GuidelineHuman Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update · 2018
  13. GuidelineGermline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline · 2024
  14. GuidelineNCCN Guidelines Updates: Breast Cancer · 2019
  15. GuidelineUpdated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG) · 2021
  16. GuidelineESR Essentials: screening for breast cancer - general recommendations by EUSOBI · 2024
  17. GuidelineACR Appropriateness Criteria(®) Breast Cancer Screening · 2017
  18. GuidelineACR Appropriateness Criteria(®) Breast Imaging of Pregnant and Lactating Women · 2018
  19. GuidelineScreening for Breast Cancer: US Preventive Services Task Force Recommendation Statement · 2024
  20. GuidelineNo. 366-Gynaecologic Management of Hereditary Breast and Ovarian Cancer · 2018
  21. GuidelineBreast cancer germline multigene panel testing in mainstream oncology based on clinical-public health utility: ESMO Precision Oncology Working Group recommendations · 2025
  22. GuidelineESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5) · 2022
  23. GuidelineManagement of Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Guideline Update · 2022
  24. GuidelinePostmastectomy Radiation Therapy: An ASTRO-ASCO-SSO Clinical Practice Guideline · 2025
  25. GuidelineACR Appropriateness Criteria® Imaging of Invasive Breast Cancer · 2024
  26. GuidelineManagement of Male Breast Cancer: ASCO Guideline · 2020
  27. GuidelineESTRO ACROP consensus guideline for target volume delineation in the setting of postmastectomy radiation therapy after implant-based immediate reconstruction for early stage breast cancer · 2019
  28. GuidelineACR Appropriateness Criteria® Imaging of Ductal Carcinoma in Situ (DCIS) · 2025
  29. GuidelineManagement of Ductal Carcinoma In Situ: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline · 2024
  30. GuidelineACR Appropriateness Criteria® Female Breast Cancer Screening: 2023 Update · 2024
  31. GuidelineSentinel Lymph Node Biopsy in Early-Stage Breast Cancer: ASCO Guideline Update · 2025
  32. GuidelineRecommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group · 2024
  33. GuidelineTumour and normal tissue radiosensitivity · 2022
  34. GuidelineHereditary diffuse gastric cancer: updated clinical practice guidelines · 2020
  35. GuidelineOncoplastic breast surgery: A guide to good practice · 2021
  36. GuidelineACR Appropriateness Criteria® Supplemental Breast Cancer Screening Based on Breast Density · 2021
  37. GuidelinePartial Breast Irradiation for Patients With Early-Stage Invasive Breast Cancer or Ductal Carcinoma In Situ: An ASTRO Clinical Practice Guideline · 2024
  38. GuidelineThe Japanese Breast Cancer Society Clinical Practice Guidelines for surgical treatment of breast cancer, 2022 edition · 2024
  39. GuidelineBreast imaging and cancer diagnosis during the COVID-19 pandemic: recommendations from the Italian College of Breast Radiologists by SIRM · 2020
  40. GuidelineAdjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update · 2019
  41. GuidelineFertility Preservation in Patients With Cancer: ASCO Clinical Practice Guideline Update · 2018
  42. GuidelineSystemic hormone therapy after breast and gynecological cancers: an Italian expert group consensus opinion · 2025
  43. GuidelineUse of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update · 2019
  44. GuidelineRadiotherapy of breast cancer · 2022
  45. GuidelineClinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment · 2017
  46. GuidelineESTRO-ACROP guideline: Recommendations on implementation of breath-hold techniques in radiotherapy · 2023
  47. GuidelineACR Appropriateness Criteria® Male Breast Cancer Screening · 2025
  48. GuidelineA guide for addressing sexual health in breast cancer patients · 2024
  49. GuidelineESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC) · 2023

What supports this page

The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.

Guideline
161
Meta-analysis
77
Systematic review
52
Randomized trial
5
Clinical trial
23
Observational
3
Case report
91
Review
1953
Preclinical
0
Other
9

Living document — last change June 20, 2026: Cancer page updated. 3 recent updates logged.

Medicines & supplements studied for Breast Invasive Ductal Carcinoma (IDC)

PubMedFDAClinicalTrials.gov

Every drug, supplement, and other agent the published studies cover for Breast Invasive Ductal Carcinoma (IDC), ranked by how strong the evidence is — what studies report, not a recommendation. Tap any to see its full profile.

Medicines · 5

CarboplatinInsufficient evidenceReported positive

No primary experimental studies yet.

Largest credible effect: adjuvant chemotherapy courses 6, n=1 PMID 37592269 · effect sizes 6–18 across 2 studies

Most authoritative study: Hereditary breast and ovarian cancer triggered by occult fallopian tube cancer: a case report

No human studies yet · Based on a single study.
Other1 studyFull profile →
FuzuloparibInsufficient evidenceReported positive

No primary experimental studies yet.

Most authoritative study: Fuzuloparib: First Approval

No human studies yet · No numeric effect sizes reported · Based on a single study.
Other1 studyFull profile →
OlaparibInsufficient evidenceReported positive

No primary experimental studies yet.

Largest credible effect: adjuvant chemotherapy courses 6, n=1 PMID 37592269 · effect sizes 6–18 across 2 studies

Most authoritative study: Hereditary breast and ovarian cancer triggered by occult fallopian tube cancer: a case report

No human studies yet · Based on a single study.
Other1 studyFull profile →
PaclitaxelInsufficient evidenceReported positive

No primary experimental studies yet.

Largest credible effect: adjuvant chemotherapy courses 6, n=1 PMID 37592269 · effect sizes 6–18 across 2 studies

Most authoritative study: Hereditary breast and ovarian cancer triggered by occult fallopian tube cancer: a case report

No human studies yet · Based on a single study.
Other1 studyFull profile →
TamoxifenInsufficient evidenceMixed results

No primary experimental studies yet.

Most authoritative study: Tamoxifen and Endometrial Cancer: A Janus-Headed Drug

No human studies yet · No numeric effect sizes reported · Based on a single study.
Hormonal therapyFDA approved1 studyFull profile →

What recent studies report in Breast Invasive Ductal Carcinoma (IDC)

These are reviewed studies whose abstracts concern Breast Invasive Ductal Carcinoma (IDC). Each describes only what that study reported. This is not a claim by OncoForge that any compound helps or harms Breast Invasive Ductal Carcinoma (IDC). Most are early lab, animal, or small human studies, and findings often conflict.

35 studies7 human1 animal⚠ Conflicting evidenceMechanism (17)Supportive care (5)Trial (2)

Tracking 35 published studies of Breast Invasive Ductal Carcinoma (IDC): 7 in humans, 1 in animals, 27 reviews/other.

Reported direction across studies: 13 positive, 10 mixed, 1 negative, 11 inconclusive.

Findings conflict — both supportive and negative/mixed results exist (see below). Human evidence is limited.

These counts summarize what the studies reported; they are not a measure of whether anything works for Breast Invasive Ductal Carcinoma (IDC).

Compounds with studies mentioning Breast Invasive Ductal Carcinoma (IDC)

Paclitaxel (1)Carboplatin (1)Olaparib (1)Fuzuloparib (1)Tamoxifen (1)
ReviewMechanismInconclusiveLimited evidenceTier 3 · early human

HER2/neu as a Signaling and Therapeutic Marker in Uterine Serous Carcinoma

Cells · Aug 2025 · review

uterine serous carcinomaendometrial cancerbreast cancer

This is a narrative review of HER2/neu as a signaling and therapeutic marker in uterine serous carcinoma (USC). It summarizes HER2 expression and amplification in USC, compares USC HER2 features to breast cancer, evaluates preclinical and clinical evidence for HER2-directed therapies (including monoclonal antibodies and ADCs), and discusses possible mechanisms of resistance.

Studied with: monoclonal antibodies, antibody-drug conjugates, chemotherapy.

Key findings
  • HER2/neu coordinates cell growth and differentiation and when overexpressed and/or amplified its downstream tyrosine kinase can become constitutively activated, causing dysregulated gene transcription.
  • HER2/neu has been successfully targeted in breast cancer with monoclonal antibodies and antibody-drug conjugates.
  • Use of HER2-directed therapies in gynecologic malignancies has been slower, in part due to unique characteristics of HER2 protein expression and gene amplification in USC such as major heterogeneity and lack of apical staining compared to breast cancer.
  • Optimal testing algorithms for HER2/neu status in USC may have important implications for developing targeted therapies.
  • The review evaluates efficacy of HER2-directed therapies in both preclinical and clinical settings and discusses possible mechanisms of resistance.
Limitations: Narrative review rather than original experimental or systematic/meta-analytic data.; Abstract contains no quantitative results or study-level sample sizes.; Conclusions depend on heterogeneous preclinical and clinical studies in the literature rather than a single controlled dataset.; Field limitations noted (e.g., heterogeneity of HER2 expression in USC) may limit generalizability of testing and therapeutic approaches..

Reviews HER2/neu expression and the potential of HER2-directed therapies in uterine serous carcinoma, with attention to diagnostic testing and resistance.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Animal studyReported positivePreclinical onlyTier 2 · animal

A humanized anaplastic lymphoma kinase (ALK)-directed antibody-drug conjugate with pyrrolobenzodiazepine payload demonstrates efficacy in ALK-expressing cancers

Nature communications · Aug 2025 · xenograft antitumor assays

neuroblastomarhabdomyosarcomacolorectal carcinomamelanomaovarian carcinomabreast carcinoma

This study tested a humanized antibody-drug conjugate called CDX0239-PBD in ALK-expressing cancer models. In cell lines, it was taken up by ALK-positive neuroblastoma cells and killed them in a way that depended on surface ALK expression. In mouse xenograft models, it produced strong antitumor activity and complete responses were maintained in several ALK-expressing cancers.

Key findings
  • ALK RNA, protein, and tumor cell surface expression was elevated in multiple pediatric and adult malignancies with minimal expression in childhood normal tissues.
  • CDX0239-PBD was internalized in ALK-expressing neuroblastoma cell lines with cell surface expression-dependent cytotoxicity.
  • CDX0239-PBD exhibited potent antitumor efficacy including maintained complete responses in ALK-expressing patient and cell line-derived neuroblastoma, fusion-positive rhabdomyosarcoma, and colorectal carcinoma xenograft models.
Limitations: Preclinical study only; no human treatment data are reported in the abstract.; Efficacy was shown in cell lines and xenograft mouse models, which may not predict clinical benefit.; No quantitative effect sizes, dosing details, or toxicity results are provided in the abstract..

The abstract describes a preclinical anticancer antibody-drug conjugate targeting ALK-expressing tumors.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Human · observationalSupportive careMixed resultsModerate evidenceTier 3 · early humann = 267586

Risk of atherosclerotic cardiovascular disease after cancer diagnosis: findings from 3 prospective cohort studies

Journal of the National Cancer Institute · Aug 2025 · prospective cohort study

Supportive carecervical cancerHodgkin lymphomaprostate cancerbreast cancercolorectal cancerlung cancerendometrial canceroral cavity and pharynx cancerkidney cancerovarian cancersarcomamelanomaleukemia

Researchers followed participants in three large prospective cohorts for up to 36 years to examine whether a cancer diagnosis was associated with later atherosclerotic cardiovascular disease (ASCVD). They documented 4,334 new ASCVD events among 49,603 incident cancer cases and found that cervical cancer and Hodgkin lymphoma were associated with higher ASCVD risk, prostate cancer with slightly lower risk, and that ASCVD risk trajectories over time varied by cancer type (for example, breast cancer survivors had lower ASCVD risk for the first 7.5 years, then risk increased).

Reported effects: new-onset ASCVD events among incident cancer cases 4334, n=49603 · cervical cancer HR 1.56 [1.06–2.29] · +6 more

Key findings
  • During up to 36 years of follow-up, 4,334 new-onset ASCVD events among 49,603 incident cancer cases were documented.
  • Cervical cancer was associated with increased ASCVD incidence (HR = 1.56, 95% CI = 1.06 to 2.29).
  • Hodgkin lymphoma was associated with increased ASCVD incidence (HR = 2.80, 95% CI = 1.89 to 4.15).
  • Prostate cancer was associated with lower ASCVD incidence (HR = 0.91, 95% CI = 0.85 to 0.97).
  • Breast cancer survivors experienced lower ASCVD risk during the first 7.5 years after diagnosis, but risk gradually increased afterward (Pnonlinearity = .01).
  • ASCVD risk increased over time among patients with cancers of the colorectum (P = .003), lung (P = .002), and endometrium (P = .04).
  • No statistically significant association with ASCVD risk was observed for cancers of the oral cavity and pharynx, kidney, or ovary; sarcoma; melanoma; or leukemia.
Limitations: Observational cohort design cannot establish causality.; Potential for residual confounding despite multivariable adjustment.; Cohorts consist of nurses and health professionals, which may limit generalizability to other populations.; Abstract does not report details on cancer stage or treatments, which could influence ASCVD risk..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Human · observationalReported positiveModerate evidenceTier 3 · early humann = 4332

Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence Variations

JAMA oncology · Apr 2024 · International longitudinal cohort study

breast cancerovarian cancerperitoneal cancer

This international cohort study followed 4,332 women with pathogenic BRCA1 or BRCA2 variants (no prior cancer) to evaluate whether self-reported bilateral oophorectomy was associated with mortality. After a mean 9.0 years, oophorectomy was associated with lower age-adjusted all-cause mortality (HR 0.32); HRs were 0.28 for BRCA1 and 0.43 for BRCA2 carriers. Estimated cumulative all-cause mortality to age 75 was lower for women who had oophorectomy at age 35 versus those who did not (BRCA1: 25% vs 62%; BRCA2: 14% vs 28%).

Reported effects: cohort_size 4332, n=4332 · deaths_total 228, n=4332 · +5 more

Key findings
  • Cohort included 4,332 women (mean age, 42.6 years); 2,932 (67.8%) underwent preventive oophorectomy at a mean age of 45.4 years.
  • After mean follow-up of 9.0 years, 851 women developed cancer and 228 died (57 ovarian/fallopian tube cancer, 58 breast cancer, 16 peritoneal cancer, 97 other causes).
  • Age-adjusted HR for all-cause mortality associated with oophorectomy: 0.32 (95% CI, 0.24-0.42; P < .001).
  • Age-adjusted HR for all-cause mortality for BRCA1: 0.28 (95% CI, 0.20-0.38; P < .001); for BRCA2: 0.43 (95% CI, 0.22-0.90; P = .03).
  • Estimated cumulative all-cause mortality to age 75 for oophorectomy at age 35 versus no oophorectomy: BRCA1 25% vs 62%; BRCA2 14% vs 28%.
Limitations: Observational cohort design with no randomization, so results may be affected by confounding.; Oophorectomy status was self-reported via questionnaire.; Potential for residual confounding or selection bias not addressed in the abstract.; Mean follow-up of 9.0 years may limit capture of longer-term outcomes..

AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Human · observationalMechanismReported positiveLimited evidenceTier 3 · early humann = 500

Identification of Bone Metastatic and Prognostic Alternative Splicing Signatures in Prostate Adenocarcinoma

Biochemical genetics · Dec 2023 · Retrospective computational analysis of TCGA and TCGASpliceSeq RNA-seq and ASE data

prostate adenocarcinomabreast cancer

The authors analyzed RNA-seq and alternative splicing event data for 500 prostate adenocarcinoma patients from TCGA and used LASSO regression to select five genes to build a prognostic prediction model. The model showed good reliability by ROC analysis and was significant in both univariate and multivariate Cox regression (both P<0.001). They constructed a putative splicing regulatory network and report that HSPB1 up-regulating PIP5K1C-46,721-AT (P<0.001) may be linked to tumorigenesis, progression and metastasis via Alzheimer’s-disease-pathway members (SRC, EGFR, MAPT, APP, PRKCA) (P<0.001).

Reported effects: sample_size 500, n=500 · Cox regression p-value, p <0.001 · +2 more

Key findings
  • RNA sequencing data and ASEs data from 500 PRAD patients were retrieved from TCGA and TCGASpliceSeq.
  • Five genes were selected by LASSO regression to construct a prognostic prediction model.
  • The prediction model had good reliability on ROC analysis (ROC curve reported as supportive in abstract).
  • Both univariate and multivariate Cox regression analyses confirmed prognostic efficacy of the model (both P<0.001).
  • A splicing regulatory network was proposed and, after multiple-database validation, HSPB1 up-regulating PIP5K1C-46,721-AT was associated with PRAD progression (P<0.001).
  • The authors suggest involvement of key members of the Alzheimer's disease pathway (SRC, EGFR, MAPT, APP, PRKCA) in this axis (P<0.001).
Limitations: Retrospective computational analysis of public datasets (TCGA/TCGASpliceSeq) without prospective clinical validation reported.; No experimental (in vitro or in vivo) functional validation of the proposed splicing events or regulatory axis is reported in the abstract.; Prognostic model performance details (e.g., AUC values, independent external cohort performance metrics) are not provided in the abstract.; Associations reported are correlative and the proposed mechanistic links are speculative based on database analyses..

This study identifies alternative splicing events and builds a prognostic splicing-signature/model associated with metastasis and prognosis in prostate adenocarcinoma using TCGA data.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Case reportInconclusiveLimited evidenceTier 3 · early humann = 1

Primary Small Cell Carcinoma of the Breast: An Approach to Medical and Surgical Management

Cureus · Oct 2023 · case report

primary small cell carcinoma of the breast

This is a single-patient case report of a 55-year-old woman diagnosed with primary small cell carcinoma of the breast. Imaging (MRI and PET) showed no metastatic disease. She underwent two lumpectomies with neoadjuvant chemotherapy given between procedures because of recurrent positive margins, then ultimately a left mastectomy followed by postoperative radiation. The authors highlight the management challenges and the lack of standardized treatment protocols for this rare tumor.

Studied with: surgery, chemotherapy, radiation therapy.

Key findings
  • Primary small cell carcinoma of the breast is rare and aggressive.
  • Biopsy showed poorly differentiated neuroendocrine small cell carcinoma.
  • MRI and PET imaging excluded metastatic disease in this patient.
  • The patient had recurrent positive margins after lumpectomy, received neoadjuvant chemotherapy between lumpectomies, and ultimately underwent left mastectomy.
  • Postoperative radiation therapy was administered after mastectomy.
  • The report emphasizes the need for standardized treatment models for PSCCB patients.
Limitations: Single-case report (n=1), so findings are not generalizable.; No details provided on chemotherapy regimen, doses, or timing.; No quantitative outcomes reported (no follow-up duration, recurrence status, or survival data).; No control or comparator; observational description only..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Case reportMechanismReported positiveLimited evidenceTier 3 · early humann = 1

Hereditary breast and ovarian cancer triggered by occult fallopian tube cancer: a case report

Journal of medical case reports · Aug 2023 · case report

PaclitaxelCarboplatinOlaparibfallopian tube cancerhigh-grade serous carcinomabreast cancerovarian neoplasmshereditary breast and ovarian cancer syndrome

A 72-year-old woman underwent hysterectomy and bilateral salpingo-oophorectomy for presumed benign disease; detailed pathology revealed incidental high-grade serous carcinoma of the right fallopian tube. Staging surgery found a single para-aortic node metastasis, a germline BRCA2 mutation was detected, she received six courses of paclitaxel plus carboplatin followed by maintenance olaparib, and she was disease-free 18 months after surgery.

Reported effects: adjuvant chemotherapy courses 6, n=1 · disease-free at 18 mo, n=1

Studied with: paclitaxel and carboplatin.

Key findings
  • Incidental detection of high-grade serous carcinoma of the right fallopian tube on detailed pathological examination.
  • Staging laparotomy confirmed a single para-aortic lymph node metastasis (FIGO Stage IIIA1(i)).
  • Postoperative detection of a germline BRCA2 mutation and diagnosis of hereditary breast and ovarian cancer syndrome.
  • Patient received adjuvant therapy: six courses of paclitaxel and carboplatin followed by maintenance olaparib.
  • Patient was free of disease 18 months after surgery.
Limitations: Single-patient case report (n=1) limits generalizability.; No control or comparison group to assess treatment effect.; Relatively short follow-up (reported disease-free status at 18 months only).; No dosing details provided for chemotherapy or olaparib in the abstract..

Illustrates that detailed pathologic examination and accurate staging can identify occult fallopian tube cancer and that germline BRCA2 testing may inform use of maintenance PARP inhibitor therapy.

AI summary of the abstract, human-reviewed · Jul 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

OtherSupportive careInconclusiveLimited evidenceTier 3 · early human

Breast Development and Cancer

Cancers · Mar 2023

Supportive carebreast cancer

This editorial discusses the role of the clinical breast exam in the diagnosis and surveillance of benign and malignant breast disease. It states that a thorough breast exam is an important clinical skill and that, when used with other evaluation methods, it provides important information for workup and management. The authors note that screening recommendations vary, but many guidelines agree a clinical breast exam is warranted for women with abnormal mammography findings and as part of annual screening for some women at increased risk.

Key findings
  • A clinical breast exam is an important skill for medical practitioners and is a key step in diagnosis and surveillance of benign and malignant breast diseases.
  • When used as part of a multimodal evaluation, the breast exam provides important information used in workup and management.
  • Recommendations for breast cancer screening intervals and tests vary across guidelines.
  • Many guidelines agree that a clinical breast exam is warranted for women with abnormal findings on mammography and as part of annual screening for certain groups of women at increased risk for breast cancer.
Limitations: Editorial rather than original research — no methods, data, or statistical analyses presented.; No sample size, patient cohort, or empirical outcomes reported.; Conclusions reflect expert commentary or synthesis rather than primary evidence..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

OtherMechanismReported positiveLimited evidenceTier 3 · early humann = 10

Impact of early detection on cancer curability: A modified Delphi panel study

PloS one · Dec 2022 · RAND/UCLA modified Delphi panel

stomachesophaguslungurothelial tractmelanomaovarysarcomabladdercervixbreastcolon/rectumkidneyuterusanushead and neckliver/intrahepatic bile ductgallbladderpancreasprostatethyroid

Ten practicing oncologists used a RAND/UCLA modified Delphi panel to rate 20 solid tumor types for potential clinical benefit from a hypothetical annual multi-cancer screening blood test. Cancers judged to progress quickly but be more curable at early stages (e.g., stomach, esophagus, lung, melanoma, ovary, sarcoma, bladder, cervix, breast, colon/rectum, kidney, uterus, anus, head and neck) were rated most likely to benefit. Cancers judged to progress quickly but with lower early-stage cure rates (liver/intrahepatic bile duct, gallbladder, pancreas) were rated as having medium likelihood of benefit. Prostate and thyroid, judged to progress more slowly and be curable regardless of stage, were rated as having limited likelihood of benefit.

Key findings
  • Expert ratings identified a group of cancers estimated most likely to benefit from a hypothetical annual multi-cancer screening blood test: stomach, esophagus, lung, urothelial tract, melanoma, ovary, sarcoma, bladder, cervix, breast, colon/rectum, kidney, uterus, anus, head and neck.
  • Cancers rated as progressing quickly but with comparatively lower cure rates in earlier stages (liver/intrahepatic bile duct, gallbladder, pancreas) were estimated to have medium likelihood of benefit.
  • Cancers rated as progressing more slowly and having higher curability regardless of stage (prostate, thyroid) were estimated to have limited likelihood of benefit.
  • The panel concluded most solid tumors have a likelihood of benefit from early detection and that early-stage detection was believed to be beneficial even among difficult-to-treat cancers (e.g., pancreas, liver/intrahepatic bile duct, gallbladder).
  • The 20 solid tumors evaluated represent >40 AJCC-identified cancer types and 80% of total cancer incidence (as stated in abstract).
Limitations: Small expert panel (10 oncologists) — results reflect opinions of a limited number of experts.; Delphi consensus of expert opinion rather than empirical patient-level outcomes or clinical trial data.; Assessment based on a hypothetical annual multi-cancer screening blood test rather than an evaluated diagnostic with measured performance.; No patient data, clinical endpoints, or real-world screening test performance reported in this study..

Expert consensus assessing which solid tumor types might gain clinical benefit from earlier detection via a hypothetical multi-cancer blood screening test.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

ReviewInconclusiveModerate evidenceTier 4 · clinical

Breast Cancer in Pregnancy: Caring for the Very Young Breast Cancer Patient from Diagnosis Through Survivorship

Obstetrics and gynecology clinics of North America · Mar 2022 · narrative review

breast cancer

This narrative review summarizes diagnosis, staging, and treatment of breast cancer diagnosed during pregnancy or within the first postpartum year (pregnancy-associated breast cancer). The authors note that breast cancer is a common malignancy in pregnancy and that incidence is increasing as more women delay childbearing. The article provides an overview of management and discusses recommendations for caring for these patients from diagnosis through survivorship.

Key findings
  • Pregnancy-associated breast cancer is defined as breast cancer diagnosed during pregnancy or in the first postpartum year.
  • Breast cancer is one of the most common malignancies to occur during pregnancy.
  • The incidence of breast cancer in pregnancy is increasing as more women delay childbearing.
  • The article provides an overview of diagnosis, staging, and treatment and discusses management recommendations for pregnancy-associated breast cancer.
Limitations: Narrative review rather than primary research—no new patient-level data reported.; Abstract does not describe methods, evidence grading, or whether the review was systematic.; No quantitative outcomes or effect sizes reported in the abstract.; Recommendations and conclusions in the review are not linked to specific data or trials in the abstract..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

ReviewMechanismMixed resultsModerate evidenceTier 4 · clinical

Causes and Consequences of Polycystic Ovary Syndrome: Insights From Mendelian Randomization

The Journal of clinical endocrinology and metabolism · Feb 2022 · Literature review of Mendelian randomization studies (search to May 2021)

breast cancer (estrogen receptor-positive)ovarian cancer (endometrioid)

This is a literature review of Mendelian randomization (MR) studies examining causes and consequences of polycystic ovary syndrome (PCOS), based on a search to May 2021. The review reports that MR evidence suggests factors such as obesity, testosterone, fasting insulin, SHBG, menopause timing, male-pattern balding, and depression may causally influence PCOS, while PCOS itself may increase risk of estrogen receptor–positive breast cancer, decrease risk of endometrioid ovarian cancer, and has no direct causal effect on type 2 diabetes, coronary heart disease, or stroke.

Key findings
  • MR studies suggest obesity, testosterone levels, fasting insulin, serum sex hormone-binding globulin concentrations, menopause timing, male-pattern balding, and depression may play a causal role in PCOS.
  • MR evidence summarized in the review indicates PCOS may increase risk of estrogen receptor–positive breast cancer.
  • MR evidence summarized in the review indicates PCOS may decrease risk of endometrioid ovarian cancer.
  • MR analyses reported in the review found no direct causal effect of PCOS on type 2 diabetes, coronary heart disease, or stroke.
Limitations: This work is a review and does not present new primary data; conclusions depend on the quality and availability of underlying GWAS and MR studies.; Search was limited to studies available up to May 2021.; Mendelian randomization analyses rely on assumptions (valid genetic instruments, absence of horizontal pleiotropy) that, if violated, can bias causal inference.; Heterogeneity in genetic instruments, populations, and outcome definitions across included MR studies may limit generalizability..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

ReviewInconclusiveLimited evidenceTier 4 · clinical

Breast cancer: presentation, investigation and management

British journal of hospital medicine (London, England : 2005) · Feb 2022

breast cancer

This is a narrative review summarising breast cancer pathology, epidemiology, clinical presentation, referral pathways and management in the UK. The authors note that breast cancer is the most common global malignancy and the leading cause of cancer deaths, and that limited undergraduate and postgraduate exposure can impair clinicians' ability to recognise, assess and refer patients. The article also describes how to perform a thorough clinical breast examination.

Key findings
  • Breast cancer is described as the most common global malignancy and the leading cause of cancer deaths.
  • Undergraduate and postgraduate exposure to breast cancer is limited, which impacts clinicians' ability to accurately recognise, assess and refer appropriate patients.
  • The article provides a comprehensive review of pathology, epidemiology, clinical presentation, referral pathways and management of breast cancer in the UK.
  • The review describes how to conduct a thorough clinical breast examination.
Limitations: Review article—no original or primary data reported in this abstract.; Scope described is UK-focused, which may limit generalisability to other health systems.; Abstract does not state whether this is a systematic review or the methods used to select evidence..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

Browse all studies mentioning Breast Invasive Ductal Carcinoma (IDC)

Where the evidence is

What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination — a gap, not evidence of no effect. Open a row to see its studies.

CompoundHuman evidenceMechanismSafetyTrial
Carboplatin1
Fuzuloparib11
Olaparib1
Paclitaxel1
Tamoxifen1

Study mix

35 published studies by what they were done in. Lab and animal findings often do not carry over to people.

7 Human1 Animal27 Review/other
Reported directionReported positive13Mixed results10Reported negative1Inconclusive11

Compounds with reported-positive results in Breast Invasive Ductal Carcinoma (IDC)

Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.

Preclinical only: lab / animal (4)
Paclitaxel1 positive
Limitations: Single-patient case report (n=1) limits generalizability.; No control or comparison group to assess treatment effect.; Relatively short follow-up (reported disease-free status at 18 months only).; No dosing details provided for chemotherapy or olaparib in the abstract..
Cited positive studies (1)
Carboplatin1 positive
Limitations: Single-patient case report (n=1) limits generalizability.; No control or comparison group to assess treatment effect.; Relatively short follow-up (reported disease-free status at 18 months only).; No dosing details provided for chemotherapy or olaparib in the abstract..
Cited positive studies (1)
Olaparib1 positive
Limitations: Single-patient case report (n=1) limits generalizability.; No control or comparison group to assess treatment effect.; Relatively short follow-up (reported disease-free status at 18 months only).; No dosing details provided for chemotherapy or olaparib in the abstract..
Cited positive studies (1)
Fuzuloparib1 positive
Limitations: Review article; no original study data in the abstract.; No efficacy or safety results are reported in the abstract.; No comparator, sample size, or quantitative outcomes are provided..
Cited positive studies (1)

Evidence at a glance: compounds studied in Breast Invasive Ductal Carcinoma (IDC)

A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.

CarboplatinInsufficient evidenceReported positive

No primary experimental studies yet.

Largest credible effect: adjuvant chemotherapy courses 6, n=1 PMID 37592269 · effect sizes 6–18 across 2 studies

Most authoritative study: Hereditary breast and ovarian cancer triggered by occult fallopian tube cancer: a case report

No human studies yet · Based on a single study.
FuzuloparibInsufficient evidenceReported positive

No primary experimental studies yet.

Most authoritative study: Fuzuloparib: First Approval

No human studies yet · No numeric effect sizes reported · Based on a single study.
OlaparibInsufficient evidenceReported positive

No primary experimental studies yet.

Largest credible effect: adjuvant chemotherapy courses 6, n=1 PMID 37592269 · effect sizes 6–18 across 2 studies

Most authoritative study: Hereditary breast and ovarian cancer triggered by occult fallopian tube cancer: a case report

No human studies yet · Based on a single study.
PaclitaxelInsufficient evidenceReported positive

No primary experimental studies yet.

Largest credible effect: adjuvant chemotherapy courses 6, n=1 PMID 37592269 · effect sizes 6–18 across 2 studies

Most authoritative study: Hereditary breast and ovarian cancer triggered by occult fallopian tube cancer: a case report

No human studies yet · Based on a single study.
TamoxifenInsufficient evidenceMixed results

No primary experimental studies yet.

Most authoritative study: Tamoxifen and Endometrial Cancer: A Janus-Headed Drug

No human studies yet · No numeric effect sizes reported · Based on a single study.

What the research shows for Breast Invasive Ductal Carcinoma (IDC)

A plain-language summary of the reviewed studies OncoForge tracks for Breast Invasive Ductal Carcinoma (IDC). It reports what those studies described, not a claim that any compound or therapy helps or harms Breast Invasive Ductal Carcinoma (IDC). Most of this evidence is early, and findings often conflict.

  • A narrative review summarized diagnosis, staging, and treatment issues for pregnancy-associated breast cancer, emphasizing clinical considerations for breast cancer that arises during pregnancy or soon after childbirth (review-level evidence, not new clinical trial data).
  • A review of nucleobindin-2/nesfatin-1 describes mixed findings linking higher expression to greater cancer cell proliferation, migration, invasion, and worse outcomes in several cancers including breast; the reports are inconsistent and based mainly on preclinical and observational data.
  • Several narrative reviews addressed breast reconstruction techniques and supportive-care aspects after mastectomy, reporting on surgical options, safety, and psychosocial outcomes rather than anticancer effects.
  • A review describing fuzuloparib focused on its development and approval for certain ovarian/fallopian/peritoneal cancers; no clinical studies of fuzuloparib in breast invasive ductal carcinoma were reported in this collection.
  • Preclinical/animal experimental work in this set involved other agents and tumor types (for example an antibody–drug conjugate tested in ALK-expressing neuroblastoma and other models), indicating that much of the mechanistic and drug-development evidence here is not specific to breast IDC.

Compounds studied in Breast Invasive Ductal Carcinoma (IDC)

Fuzuloparib1 study
These collected studies do not report clinical data for fuzuloparib in invasive ductal carcinoma of the breast; a cited review described fuzuloparib as an oral PARP inhibitor with clinical development and regulatory approval for certain ovarian/fallopian/peritoneal cancers, so evidence specific to breast IDC is lacking in this set (main limitation: no breast-specific studies here).

Supportive & alternative options discussed

  • Exercise / prehabilitation: Also discussed as a supportive option for improving physical function, fatigue, and quality of life during and after breast cancer treatment.
  • Mind–body (MBSR / CBT): Also discussed as a supportive option for managing distress, anxiety, and quality-of-life concerns in people with breast cancer.
  • Acupuncture: Also discussed as a supportive option for symptom management (for example, pain or hot flashes) in the context of breast cancer care.
  • Mistletoe (VAE): Also discussed in some settings as a complementary therapy used by patients with breast cancer, though high-quality evidence from these collected studies is not provided.

What we don’t know yet

  • Are PARP inhibitors such as fuzuloparib safe and effective for patients with invasive ductal carcinoma of the breast, and if so, which patient subgroups (for example, BRCA-mutated) might benefit?
  • What are appropriate dosing, scheduling, and safety profiles of fuzuloparib in breast cancer—no breast-specific clinical pharmacology or trial data are provided here.
  • Is nucleobindin-2/nesfatin-1 a reliable prognostic or predictive biomarker in breast IDC given the inconsistent findings and predominance of preclinical/observational studies?
  • How do pregnancy-associated breast cancer management strategies affect long-term maternal and oncologic outcomes—existing reports are narrative summaries rather than prospective trial data.
  • Do the preclinical findings from other tumor types or experimental agents translate to breast IDC, and which preclinical models best predict clinical results for this cancer?
Overall, the evidence in this collection is preliminary and comprised mainly of narrative reviews, preclinical reports, and studies in non-breast cancers, so it does not establish clinical benefits or clear guidance for invasive ductal carcinoma of the breast.

Clinical trials in Breast Invasive Ductal Carcinoma (IDC)

0 ongoing · 1 completed · tracked from ClinicalTrials.gov. Recruiting is not the same as proven, and completed is not the same as positive — read the results. Not a recommendation.

Completed

Search all trials on ClinicalTrials.gov →

Getting care & support

Nonprofit / Gov

Practical, vetted help for Breast Invasive Ductal Carcinoma (IDC) — advocacy, paying for treatment, second opinions, and caregivers.

If you’re struggling emotionally, you don’t have to wait.

Advocacy & community

No dedicated organization for this specific cancer is curated yet — these general organizations can help in the meantime.

Financial help

  • PAN FoundationCopay assistance funds by diagnosis (funds open and close as money allows). · status changes often — check the fund’s site
  • HealthWell FoundationCopay and premium assistance funds by disease. · status changes often — check the fund’s site
  • CancerCare — financial assistanceLimited grants plus free financial counseling. · status changes often — check the fund’s site
  • Family ReachHelp with everyday living costs (rent, transport, food) during treatment. · status changes often — check the fund’s site
  • NeedyMedsSearchable directory of drug patient-assistance and discount programs. · status changes often — check the fund’s site
What you’ll typically need to apply
  • Your diagnosis and, if you have it, the specific drug/treatment name (from your care team).
  • Insurance details — your member ID card, or a note that you're uninsured (some funds require active insurance, some don't).
  • Proof of income and household size (recent pay stubs, a tax return, or a benefits letter) — most funds are income-based.
  • Your prescriber's contact information; some programs need the clinic to submit part of the application.
  • Apply early and re-check: funds open and close as money is available, so a closed fund may reopen.

General guidance — each program sets its own eligibility. Confirm requirements on the program’s site.

Help paying for the medicines on this page

Second opinions

Caregiver support

We list only non-profit and government resources — never product sellers — and take no affiliate fees. If a link is broken or a resource doesn't meet that bar, tell us.

Heading to an appointment? Get a printable one-page summary — studied compounds, open trials, interactions, and questions to ask.
Bring this to your appointment →

Biomarkers — what to test for, and what it could unlock

PubMedFDA

A positive result may make you eligible for the linked options — it doesn’t mean a treatment will work, and not every test is standard everywhere. Confirm testing and results with your care team.

Many of these can be checked at once from a single tumor (or blood) sample — ask your team whether a comprehensive multi-gene (NGS) panel is right for you, rather than one test at a time.

AKT1 mutation / PTEN lossPI3K–AKT pathway activation · occasionalPrognostic / other

How it’s tested: NGS panel (tumor; ± ctDNA at progression)

Pre-screen recruiting trials for AKT1 mutation / PTEN loss

Hereditary cancer gene — a germline (inherited) result can affect blood relatives. Consider genetic counseling ↗; your team can advise whether germline testing is right for you.

Androgen receptor (AR) expressionTNBC/luminal subset biology · variablePrognostic / other

Pre-screen recruiting trials for Androgen receptor (AR) expression

BRCA1/2 (germline) / PALB2homologous recombination deficiency · occasionalPrognostic / other

How it’s tested: Germline testing (BRCA1/2, PALB2, etc.)

Pre-screen recruiting trials for BRCA1/2 (germline) / PALB2

Hereditary cancer gene — a germline (inherited) result can affect blood relatives. Consider genetic counseling ↗; your team can advise whether germline testing is right for you.

CCNE1 amplification / high cyclin Ecell-cycle bypass (CDK2 activation) · occasionalPrognostic / other

How it’s tested: PD-L1 CPS (TNBC)

Pre-screen recruiting trials for CCNE1 amplification / high cyclin E

CHEK2 / ATM (germline)moderate-penetrance susceptibility · occasionalPrognostic / other

How it’s tested: Germline testing (BRCA1/2, PALB2, etc.)

Pre-screen recruiting trials for CHEK2 / ATM (germline)

Hereditary cancer gene — a germline (inherited) result can affect blood relatives. Consider genetic counseling ↗; your team can advise whether germline testing is right for you.

ER (estrogen receptor)endocrine driver · commonPrognostic / other

Pre-screen recruiting trials for ER (estrogen receptor)

ERBB2 (HER2) activating mutation (non-amplified)kinase activation in HER2-non-amplified tumors · occasionalPrognostic / other

How it’s tested: ER/PR/HER2/Ki-67 (core IHC ± ISH)

Pre-screen recruiting trials for ERBB2 (HER2) activating mutation (non-amplified)

ESR1 mutationacquired endocrine resistance (LBD) · occasionalPrognostic / other

How it’s tested: NGS panel (tumor; ± ctDNA at progression)

Pre-screen recruiting trials for ESR1 mutation

FGFR1 amplificationendocrine resistance biology (subset of HR+) · occasionalPrognostic / other

Pre-screen recruiting trials for FGFR1 amplification

GATA3 / MAP3K1 mutationsluminal lineage and favorable biology (context) · commonPrognostic / other

Pre-screen recruiting trials for GATA3 / MAP3K1 mutations

Genomic assay: Oncotype DX Recurrence Scorechemo benefit prediction in HR+/HER2–, node-negative (selected node-positive) early disease · commonPrognostic / other

How it’s tested: Genomic assay (Oncotype DX / MammaPrint in eligible HR+/HER2–)

Pre-screen recruiting trials for Genomic assay: Oncotype DX Recurrence Score

Genomic assays: MammaPrint / Prosigna (PAM50) / EndoPredictrisk stratification in HR+/HER2– early disease · occasionalPrognostic / other

How it’s tested: Genomic assay (Oncotype DX / MammaPrint in eligible HR+/HER2–)

Pre-screen recruiting trials for Genomic assays: MammaPrint / Prosigna (PAM50) / EndoPredict

HER2 (ERBB2) amplification/overexpressiongrowth factor receptor · occasionalPrognostic / other

How it’s tested: ER/PR/HER2/Ki-67 (core IHC ± ISH)

Pre-screen recruiting trials for HER2 (ERBB2) amplification/overexpression

HER2-low phenotypeADC target phenotype (not HER2+) · commonPrognostic / other

How it’s tested: ER/PR/HER2/Ki-67 (core IHC ± ISH)

Pre-screen recruiting trials for HER2-low phenotype

HER3 (ERBB3) expressionADC target (investigational) · variablePrognostic / other

Pre-screen recruiting trials for HER3 (ERBB3) expression

Homologous recombination deficiency (HRD) score/genomic scarDNA repair deficiency signature · variablePrognostic / other

How it’s tested: Genomic assay (Oncotype DX / MammaPrint in eligible HR+/HER2–)

Pre-screen recruiting trials for Homologous recombination deficiency (HRD) score/genomic scar

Ki-67proliferation index · variablePrognostic / other

How it’s tested: ER/PR/HER2/Ki-67 (core IHC ± ISH)

Pre-screen recruiting trials for Ki-67

MSI-H/dMMRmismatch repair deficiency · rarePrognostic / other

Pre-screen recruiting trials for MSI-H/dMMR

NTRK1/2/3 fusiontumor-agnostic driver · rarePrognostic / other

Pre-screen recruiting trials for NTRK1/2/3 fusion

PD-L1 (CPS)immunotherapy biomarker (TNBC) · variablePrognostic / other

How it’s tested: PD-L1 CPS (TNBC)

Pre-screen recruiting trials for PD-L1 (CPS)

PIK3CA mutationPI3K pathway activation · commonPrognostic / other

How it’s tested: NGS panel (tumor; ± ctDNA at progression)

Pre-screen recruiting trials for PIK3CA mutation

PR (progesterone receptor)luminal signaling; prognostic · commonPrognostic / other

Pre-screen recruiting trials for PR (progesterone receptor)

RB1 lossCDK4/6 inhibitor resistance biology · occasionalPrognostic / other

Pre-screen recruiting trials for RB1 loss

Hereditary cancer gene — a germline (inherited) result can affect blood relatives. Consider genetic counseling ↗; your team can advise whether germline testing is right for you.

TMB-highimmunotherapy biomarker · rarePrognostic / other

How it’s tested: NGS panel (tumor; ± ctDNA at progression)

Pre-screen recruiting trials for TMB-high

TP53 (germline, Li-Fraumeni syndrome)cancer predisposition; radiosensitivity · rarePrognostic / other

How it’s tested: Germline testing (BRCA1/2, PALB2, etc.)

Pre-screen recruiting trials for TP53 (germline, Li-Fraumeni syndrome)

Hereditary cancer gene — a germline (inherited) result can affect blood relatives. Consider genetic counseling ↗; your team can advise whether germline testing is right for you.

TP53 mutationgenome stability/tumor suppressor · commonPrognostic / other

Pre-screen recruiting trials for TP53 mutation

Hereditary cancer gene — a germline (inherited) result can affect blood relatives. Consider genetic counseling ↗; your team can advise whether germline testing is right for you.

TROP-2 expressionADC target biology · commonPrognostic / other

Pre-screen recruiting trials for TROP-2 expression

Tumor-infiltrating lymphocytes (TILs)immune prognostic marker (especially TNBC) · variablePrognostic / other

How it’s tested: NGS panel (tumor; ± ctDNA at progression)

Pre-screen recruiting trials for Tumor-infiltrating lymphocytes (TILs)

Marker → medicine links are derived from this page’s published claims for Breast Invasive Ductal Carcinoma (IDC); resistance and companion-diagnostic notes appear only where an established, sourced entry exists.

Go deeper

Questions to ask your oncologist

  • Which subtype do I have (luminal A/B, HER2+, TNBC) and what is our best curative plan?
  • Do I need neoadjuvant therapy to increase breast conservation and tailor adjuvant options by response (pCR vs residual)?
  • Will a genomic assay (e.g., Oncotype DX) change whether I need chemotherapy?
  • Am I a candidate for lumpectomy with oncoplastic techniques, or is mastectomy preferable?
  • Do I qualify for Z0011-type omission of axillary dissection or targeted axillary dissection after neoadjuvant therapy?
  • What radiation fields (breast/chest wall, nodes) and schedule (hypofractionation, 5-fraction, boost) fit my case?
  • How does reconstruction timing interact with radiation to optimize outcomes?
  • Am I eligible for CDK4/6, PI3K/AKT/mTOR, PARP inhibitors, or ADCs (T-DXd, sacituzumab)?
  • Should we test for ESR1/PIK3CA/AKT1/PTEN through ctDNA now or at progression to direct targeted therapy?
  • What is our cardiac monitoring plan on HER2 therapy or anthracyclines?
  • How will we detect and manage ILD risk on T-DXd and stomatitis on everolimus?
  • What’s the plan for diarrhea on abemaciclib/capecitabine and hyperglycemia/rash on alpelisib/capivasertib?
  • Should I pursue fertility preservation before chemo, and how would ovarian suppression fit in?
  • Can I pause endocrine therapy in the future for pregnancy under supervision?
  • How will we prevent lymphedema and bone loss, and what are my DEXA and bone-agent plans?
  • Which clinical trials fit my biomarkers (ESR1, PIK3CA, BRCA/PALB2, HER2-low)?
  • What is our imaging and clinic follow-up cadence during and after treatment?
  • What support do you offer for fatigue, cognitive changes, sexual health, and return to work?
  • Can I use scalp cooling and hand–foot cryotherapy with my regimen?

Find a trial

Citations

  1. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer

    NCCN

    • Subtype-driven systemic therapy
    • Radiation fields
    • Survivorship surveillance
  2. ESMO Guidelines: Early and Metastatic Breast Cancer

    ESMO

    • Neoadjuvant strategies (TNBC, HER2+)
    • Targeted therapy sequences
    • ADC use
  3. ASCO Guidelines & St Gallen Consensus

    ASCO

    • Genomic assay use in HR+/HER2–
    • Endocrine therapy duration
    • CDK4/6, PI3K, AKT recommendations

FAQs

What does HER2-low mean and why does it matter?
  • HER2-low (IHC 1+ or 2+ with negative ISH) is not classic HER2-positive, but in metastatic settings it can respond to trastuzumab deruxtecan (T-DXd).
Do I need chemotherapy if my tumor is ER+/HER2– and node-negative?
  • A genomic assay (e.g., Oncotype DX) often guides whether chemo adds benefit beyond endocrine therapy in early HR+/HER2– disease.
How long is endocrine therapy?
  • Typically 5 years; 7–10 years for selected higher-risk cases depending on tolerance and recurrence risk.
Is immunotherapy helpful?
  • Pembrolizumab is incorporated for high-risk early TNBC (neoadjuvant + adjuvant) and for PD-L1-positive metastatic TNBC with chemotherapy.
If I have a BRCA mutation, what changes?
  • PARP inhibitors can be used in high-risk early and metastatic settings; surgical and family planning considerations also apply.
If I have a BRCA or PALB2 mutation, what changes?
  • PARP inhibitors are options in high-risk early HER2– disease and metastatic settings. You’ll also discuss surgical choices (e.g., risk-reducing strategies) and family testing.
When is neoadjuvant (pre-op) therapy preferred?
  • Common for stage II–III HER2+ and TNBC to improve breast conservation and to adapt adjuvant therapy by pathologic response (e.g., T-DM1 for residual HER2+, capecitabine for residual TNBC). It’s considered in some HR+ cases with bulky nodes or to test endocrine sensitivity.
Why does pathologic complete response (pCR) matter?
  • In HER2+ and TNBC, pCR correlates with excellent outcomes. Residual disease triggers proven, response-adapted adjuvant options that reduce recurrence risk.
Who benefits from adjuvant abemaciclib?
  • Selected high-risk, node-positive HR+/HER2– patients after surgery and chemo/endocrine therapy. Criteria are strict; discuss exact eligibility with the team.
What if my tumor develops an ESR1 mutation?
  • ESR1 (often after aromatase inhibitors) signals endocrine resistance. Switching to a SERD (e.g., fulvestrant; oral SERDs where available) can restore control. ctDNA testing can detect ESR1 and guide timing.
I have a PIK3CA mutation—what changes?
  • In metastatic HR+/HER2– disease after aromatase inhibitor exposure, alpelisib + fulvestrant is a targeted option. You’ll need proactive management of hyperglycemia and rash.
How are brain metastases handled, especially in HER2+ disease?
  • Local therapies (SRS/surgery) plus HER2-active systemic agents with CNS activity (e.g., tucatinib-based regimens or T-DXd depending on scenario) are commonly used. Multidisciplinary planning is key.
What are the big safety watch-outs with T-DXd (trastuzumab deruxtecan)?
  • Interstitial lung disease/pneumonitis can be serious. Report new cough, fever, or shortness of breath immediately; early hold and evaluation improve outcomes.
Is sacituzumab govitecan only for TNBC?
  • It’s established after prior lines in metastatic TNBC and is also used later-line in HR+ disease after endocrine and targeted therapies. Neutropenia and diarrhea are the main toxicities to plan for.
Do positive margins always require re-excision?
  • After lumpectomy, standard is ‘no ink on tumor’ for invasive cancer. Close but negative margins typically do not require re-excision if whole-breast RT with a boost is planned.
Will I need a full axillary dissection?
  • Not always. Sentinel node biopsy is standard when nodes are clinically negative. Targeted, limited axillary approaches after neoadjuvant therapy can spare morbidity in selected responders.
Can I have immediate reconstruction if I may need radiation?
  • Yes, but plans should be coordinated. Radiation after reconstruction can affect cosmetic outcomes and complication rates; your team will time and tailor reconstruction accordingly.
How long is radiation after lumpectomy?
  • Modern whole-breast RT can be delivered in 3–5 weeks, and many patients qualify for hypofractionated or even 5-fraction regimens depending on anatomy and risk.
Do I need nodal radiation?
  • Indications depend on nodal burden, tumor biology, and response to neoadjuvant therapy. Your radiation oncologist will map fields (axillary, supraclavicular, internal mammary) case-by-case.
What follow-up do I need after treatment?
  • History/physical at regular intervals and annual mammography of the conserved breast. Routine CT/PET or tumor markers are not recommended when you’re asymptomatic.
How do we protect my bones on aromatase inhibitors?
  • Vitamin D/calcium, weight-bearing exercise, baseline and periodic DEXA scans, and—when appropriate—adjuvant bisphosphonates to reduce fractures and possibly recurrence.
Can I prevent or treat lymphedema?
  • Prehab education, early PT/OT, compression as needed, and progressive weight training reduce risk and improve function. Report arm swelling or tightness early.
What about fertility and pregnancy after breast cancer?
  • Discuss fertility preservation before chemo (oocyte/embryo freezing). Many can safely conceive later; timing depends on subtype and risk. Coordinate pauses in endocrine therapy only within a supervised plan.
Can I use vaginal estrogen for dryness on endocrine therapy?
  • Non-hormonal moisturizers and pelvic PT are first-line. Low-dose vaginal estrogen can be considered selectively after oncology review, balancing symptom relief and theoretical risks.
Which lifestyle steps matter most for recurrence reduction?
  • Physical activity, weight management, limiting alcohol, and not smoking have the strongest associations. A dietitian can personalize protein/energy goals to maintain treatment intensity.
Do cold caps really work?
  • Scalp cooling significantly reduces chemo-induced alopecia for many regimens when used correctly before/during/after infusions. Not all drugs are compatible; discuss specifics with your infusion center.
Should I get ctDNA (liquid biopsy) after surgery to detect MRD?
  • ctDNA is promising but not yet standard for changing adjuvant therapy in IDC. It may be useful at progression to identify ESR1/PIK3CA and other targets for metastatic care.
Are TILs (tumor-infiltrating lymphocytes) measured routinely?
  • TILs are mainly prognostic in TNBC and can correlate with chemo/IO response. They’re not a stand-alone decision tool but add context.

What we don't know yet

  • Optimal sequencing of targeted agents after CDK4/6 exposure.
  • Best strategies for endocrine-resistant ESR1-mutant disease beyond current SERDs.
  • Definitive role of ctDNA MRD to escalate/de-escalate adjuvant therapy.
  • Selection between ADCs in later-line HR+ disease.